Archive for the ‘Bone Marrow Stem Cells’ Category
Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference – GuruFocus.com
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. ( JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42nd Annual Growth Stock Conference, to be held in Chicago from June 6-9, 2022.
Ronald Martell, Jaspers Chief Executive Officer, is scheduled to present on Thursday, June 9th at 8:00AM CT, with a breakout session to follow at 8:40AM CT. A live webcast of the presentation will be available at https://wsw.com/webcast/blair66/jasp/1933236 and at the Companys Investor Events webpage.
About Jasper TherapeuticsJasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective, and potentially curative, allogeneic hematopoietic cell transplants and gene therapies. A clinical study of JSP191 as a novel, disease-modifying, therapeutic for patients with lower risk MDS is also planned to begin in 2022. In parallel, Jasper Therapeutics, Inc. is advancing its preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.
Forward-Looking StatementsCertain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential of the Companys JSP191 and mRNA engineered stem cell graft programs. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jaspers product candidates; the risk that prior study results may not be replicated; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]
Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]
Visit link:
Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference - GuruFocus.com
What New Advances are there in 3D Bioprinting Tissues? – AZoM
A paper recently published in the journal Biomaterials reviewed the new advances in three-dimensional bioprinting (3DBP) for regenerative therapy in different organ systems.
Study:Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Image Credit:luchschenF/Shutterstock.com
Organ/tissue shortage has emerged as a significant challenge in the medical field due to patient immune rejections and donor scarcity. Moreover, mimicking or predicting the human disease condition in the animal models is difficult during preclinical trials owing to the differences in the disease phenotype between animals and humans.
3DBP has gained significant attention as a highly-efficient multidisciplinary technology to fabricate 3D biological tissue with complex composition and architecture. This technology allows precise assembly and deposition of biomaterials with donor/patients cells, leading to the successful fabrication of organ/tissue-like structures, preclinical implants, and in vitro models.
In this study, researchers reviewed the 3DBP strategies currently used for regenerative therapy in eight organ systems, including urinary, respiratory, gastrointestinal, exocrine and endocrine, integumentary, skeletal, cardiovascular, and nervous systems. Researchers also focused on the application of 3DBP to fabricate in vitro models. The concept of in situ 3DBP was discussed.
In this extensively used low-cost bioprinting method, rotating screw gear or pressurized air is used without or with temperature to extrude a continuous stream of thermoplastic or semisolid material. Different materials can be printed at a high fabrication speed using this technology. However, low cell viability and the need for post-processing are the major drawbacks of extrusion bioprinting.
In this method, liquid drops are ejected on a substrate by acoustic or thermal forces. High fabrication speed, small droplet volume, and interconnected micro-porosity gradient in the fabricated 3D structures are the main advantages of this technique. However, limited printed materials and clogging are the biggest drawbacks of inkjet bioprinting.
A laser is used to induce the forward transfer of biomaterials on a solid surface in the laser-assisted bioprinting method. High cell viability and nozzle-free noncontact process are the biggest advantages of laser-assisted bioprinting, while metallic particle contamination and the time-consuming nature of the printing process are the major disadvantages.
Several studies were performed involving the development of neuronal tissues using the 3DBP method. The pressure extrusion/syringe extrusion (PE/SE) bioprinting technique was used for central nervous tissue (CNS) tissue replacement. The layered porous structure was fabricated using glial cells derived using human induced pluripotent stem cell (iPSC) and a novel bioink based on agarose, alginate, and carboxymethyl chitosan (CMC) formed synaptic networks and displayed a bicuculline-induced enhanced calcium response.
Similarly, stereolithography (SLA) was used to fabricate a 3D scaffold for CNS and the viability of the scaffold was evaluated for regenerative medicine application. Layered linear microchannels were printed using poly(ethylene glycol) diacrylate-gelatin methacrylate (PEGDA-GelMA) and rat E14 neural progenitor cells (NPCs). The 3D scaffold restored the synaptic contacts and significantly improved the functional outcomes. Cyclohexane was used to bond polystyrene fibers to matrix bundle terminals during crosslinking.
Multiphoton excited 3-dimensional printing (MPE-3DP) was employed for the regeneration of myocardial tissue. A layer-by-layer structure was fabricated using GelMA/ sodium 4-[2-(4-morpholino)benzoyl-2-dimethylamino]-butylbenzenesulfonate (MBS) and human hciPSC-derived cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs). The crosslinking was performed by photoactivation. The structure promoted electromechanical coupling and improved cell proliferation, vascularity, and cardiac function.
Fused deposition modeling (FDM) and PE/SE bioprinting method were used for complex tissue and organ regeneration. A micro-fluid network heart shape structure was fabricated using polyvinyl alcohol (PVA), agarose, sodium alginate, and platelet-rich plasma and rat H9c2 cells and human umbilical vein endothelial cells (HUVECs). 2% calcium dichloride was used during the crosslinking mechanism. The fabricated structure possessed a valentine heart with hollow mechanical properties and a self-defined height.
SE printing was utilized to fabricate a capillary-like network using collagen type1/ xanthan gum and human fibroblasts and ECs for applications in blood vessels. The fabricated network possessed endothelial networks and sprouting between the fibroblast layers.
Bone, cartilage, and skeletal muscle tissue can be repaired and regenerated using the 3DBP technique. For instance, FDM printing was used to print multifunctional therapeutic scaffolds for the treatment of bone. Filopodial projections were fabricated using polylactic acid (PLA) platform loaded with hyaluronic acid (HA)/ iron oxide nanoparticles (IONS)/ minocycline and human MG-63 and human bone marrow stromal cells (hBMSCs), which improved the osteogenic stimulation of the IONS and HA.
PE/SE method was used to fabricate disks and cuboid-shaped scaffolds using - tricalcium phosphate (TCP) microgel and human fetal osteoblast (hFOB) and bone marrow-derived mesenchymal stem cell (BM-MSC) for bone repair, multicellular delivery, and disease model. The fabricated structures promoted osteogenesis.
PE/SE bioprinting was also utilized to fabricate complex porous layered cartilage-like structures using alginate/gelatin/HA, rat bone marrow mesenchymal stem cells (BMSCs), and cow cardiac progenitor cells (CPCs) for hyaline cartilage regeneration. The CPCs upregulated gene expression of proteoglycan 4 (PRG4), SRY-box transcription factor 9 (SOX9), and collagen II.
PE/SE printing was also used to fabricate multinucleated, highly-aligned myotube structures using polyurethane (PU), poly(-caprolactone) (PCL), and mouse C2C12 myoblasts and NIH/3T3 fibroblasts for in-situ expansion and differentiation of skeletal muscle tendon. The fabricated constructs demonstrated more than 80% cell viability with initial tissue differentiation and development.
SLA bioprinting technique was used to fabricate bi-layered epidermis-like structure using collagen type I, mouse NIH 3T3 fibroblast cells, and human keratinocyte cells for tissue model and engineering. The fabricated constructs effectively imitated the tissue functions.
Similarly, PE was employed to fabricate microporous structures using human amniotic mesenchymal stem cells (AFSCs) and heparin-HA-PEGDA for wound healing. The construct improved the wound closure and reepithelialization, increased extracellular matrix synthesis and vascularization, and prolonged the cell paracrine activity.
PE technique was utilized to prepare a multilayered cornea-like structure using human keratocytes and methacrylated collagen (ColMA)-alginate. The cell viability of the keratocytes decreased from 90% to 83% after printing.
PE/SE bioprinting was utilized to bioprint multilayered liver-like structures using GeIMA and human HepG2/C3A for liver tissue engineering. Similarly, hepatocytes were also bioprinted to fabricate multiple organ precursors with branching vasculature. A small intestine model with improved intestinal function and high cell proliferation was fabricated using caco-2 cell-loaded polyethylene vinyl acetate (PEVA) scaffold.
Spheroids of mesenchymal stem cells (MSCs) and chondrocytes and lung endothelial cells were utilized to fabricate scaffold-free tracheal transplant. After implantation in the rat model, the matured spheroids displayed excellent vasculogenesis, chondrogenesis, and mechanical strength. FDM technique was used to fabricate a glomerular structure for kidneys using human iPSCs and hydrogel and a hollow porous network using poly(lactic-co-glycolic acid (PLGA)/PCL/tumor-associated endothelial cells (TECs) for the urethra.
In in-situ bioprinting, the tissue is directly printed on the specific defect or wound site in the body for regenerative and reparative therapy. This method provides a well-defined structure and reduces the gap between host-implant interfaces. In-situ bioprinting is better than in vitro bioprinting techniques as the patients body, as a natural bioreactor, provides a natural microenvironment.
Several studies have evaluated this technique for tissue regeneration. For instance, PE/SE method was used for skin tissue regeneration in pigs and mice using fibrin/collagen/HA and human fibroblast cells. Skin-laden sheets of consistent composition, thickness, and width were formed upon rapid crosslinking of biomaterial. PE/SE technique was also used for neural tissue regeneration in mice using agarose/CMC/alginate and human iPSCs.
In vitro models provide significant assistance in understanding the mechanism of therapeutics and disease pathophysiology. Recently, in vitro models of human tissues and organs were engineered using 3DBP technology for safety assessment and drug testing.
In the 3DBP of organs and tissues, biomaterials play a crucial role in maintaining cellular viability, providing support, and long-term acceptance. Specifically, bioinks must possess unique properties, such as cell growth promotion and structural stability, that can be optimized for clinical use. Additionally, bioinks must be compatible with printers for high-precision rapid prototyping.
Bioinks fulfilling all of these requirements are yet to be identified. Moreover, managing the time during the bioprinting of the constructs is another major challenge, as the time required to fabricate them is often more than the survival time of cells. A bioreactor platform that supports organoid growth and provides time for tissue remodeling can be used to overcome this challenge. Ethical challenges and issues are also a hurdle since fabricating internal tissues/organs can lead to liability and biosafety concerns.
In the future, 3DBP can provide novel solutions to engineer organs/tissues and revolutionize modern healthcare and medicine if these challenges can be addressed.
More from AZoM: Building Durable and Sustainable Futures with [emailprotected]
Jain, P., Kathuria, H., Dubey, N. Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Biomaterials 2022. https://www.sciencedirect.com/science/article/abs/pii/S0142961222002794?via%3Dihub
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.
Here is the original post:
What New Advances are there in 3D Bioprinting Tissues? - AZoM
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation | Bone Marrow Transplantation -…
Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cmara R, Corbacioglu S. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021. https://doi.org/10.1038/s41409-021-01227-8.
Article PubMed PubMed Central Google Scholar
D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177e182.
Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn B-M, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:53743.
CAS PubMed Article Google Scholar
Sun Y-Q, He G-L, Chang Y-J, Xu L-P, Zhang X-H, Han W, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94:1699705.
CAS PubMed Article Google Scholar
de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, et al. Innate immune recovery predicts CD4+ T cell reconstitution after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:81926.
PubMed Article CAS Google Scholar
Velardi E, Clave E, Arruda LCM, Benini F, Locatelli F, Toubert A. The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment. Semin Immunopathol. 2021;43:10117.
PubMed Article Google Scholar
de Koning C, Nierkens S, Boelens JJ. Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood. 2016;128:260715.
PubMed Article CAS Google Scholar
Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4:725.
CAS PubMed Google Scholar
Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20:83346.
CAS PubMed PubMed Central Article Google Scholar
Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med. 2013;19:695703.
CAS PubMed PubMed Central Article Google Scholar
Cao X, Wu X, Frassica D, Yu B, Pang L, Xian L, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci USA. 2011;108:160914.
CAS PubMed PubMed Central Article Google Scholar
Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. Blood. 2019;133:10318.
CAS PubMed Article Google Scholar
Kong Y, Chang Y-J, Wang Y-Z, Chen Y-H, Han W, Wang Y, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:146573.
PubMed Article Google Scholar
Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domnguez , et al. The bone marrow microenvironment at single-cell resolution. Nature. 2019;569:2228.
CAS PubMed PubMed Central Article Google Scholar
Baccin C, Al-Sabah J, Velten L, Helbling PM, Grnschlger F, Hernndez-Malmierca P, et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat Cell Biol. 2020;22:3848.
CAS PubMed Article Google Scholar
Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508:26973.
CAS PubMed PubMed Central Article Google Scholar
Simsek T, Kocabas F, Zheng J, DeBerardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7:38090.
CAS PubMed PubMed Central Article Google Scholar
Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1 level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7:391402.
CAS PubMed Article Google Scholar
Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502:63743.
CAS PubMed PubMed Central Article Google Scholar
Mndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:82934.
PubMed PubMed Central Article CAS Google Scholar
Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124:40721.
CAS PubMed Article Google Scholar
Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature. 2016;532:3238.
CAS PubMed PubMed Central Article Google Scholar
Kenswil KJG, Pisterzi P, Snchez-Duffhues G, van Dijk C, Lolli A, Knuth C, et al. Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell. 2021;28:65370.
CAS PubMed Article Google Scholar
Kenswil KJG, Jaramillo AC, Ping Z, Chen S, Hoogenboezem RM, Mylona MA, et al. Characterization of endothelial cells associated with hematopoietic niche formation in humans identifies IL-33 as an anabolic factor. Cell Rep. 2018;22:66678.
CAS PubMed Article Google Scholar
Renders S, Svendsen AF, Panten J, Rama N, Maryanovich M, Sommerkamp P, et al. Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1. Nat Commun. 2021;12:115.
Article CAS Google Scholar
Xu C, Gao X, Wei Q, Nakahara F, Zimmerman SE, Mar J, et al. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. Nat Commun. 2018;9:113.
Article CAS Google Scholar
Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21:160519.
CAS PubMed PubMed Central Article Google Scholar
Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481:45762.
CAS PubMed PubMed Central Article Google Scholar
Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, Kobayashi M, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4:26374.
CAS PubMed PubMed Central Article Google Scholar
Kopp H-G, Avecilla ST, Hooper AT, Shmelkov SV, Ramos CA, Zhang F, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005;106:50513.
CAS PubMed PubMed Central Article Google Scholar
Poulos MG, Guo P, Kofler NM, Pinho S, Gutkin MC, Tikhonova A, et al. Endothelial jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep. 2013;4:102234.
CAS PubMed PubMed Central Article Google Scholar
Guo P, Poulos MG, Palikuqi B, Badwe CR, Lis R, Kunar B, et al. Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J Clin Investig. 2017;127:424256.
PubMed PubMed Central Article Google Scholar
Chen Q, Liu Y, Jeong HW, Stehling M, Dinh VV, Zhou B, et al. Apelin+ endothelial niche cells control hematopoiesis and mediate vascular regeneration after myeloablative injury. Cell Stem Cell. 2019;25:768.e6.
CAS PubMed PubMed Central Article Google Scholar
Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol. 2020;190:50819.
PubMed PubMed Central Article Google Scholar
Poulos MG, Ramalingam P, Gutkin MC, Llanos P, Gilleran K, Rabbany SY, et al. Endothelial transplantation rejuvenates aged hematopoietic stem cell function. J Clin Investig. 2017;127:416378.
PubMed PubMed Central Article Google Scholar
Kim MM, Schlussel L, Zhao L, Himburg HA. Dickkopf-1 treatment stimulates hematopoietic regenerative function in infused endothelial progenitor cells. Radiat Res. 2019;192:5362.
CAS PubMed PubMed Central Article Google Scholar
Ju W, Lu W, Ding L, Bao Y, Hong F, Chen Y, et al. PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation. J Biomed Sci. 2020;27:113.
Article CAS Google Scholar
Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide. Blood. 2002;100:33440.
CAS PubMed Article Google Scholar
Kong Y, Wang Y, Zhang YY, Shi MM, Mo XD, Sun YQ, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3:130317.
CAS PubMed PubMed Central Article Google Scholar
Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21:101924.
CAS PubMed Article Google Scholar
Tormin A, Li O, Brune JC, Walsh S, Schtz B, Ehinger M, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood. 2011;117:506777.
CAS PubMed PubMed Central Article Google Scholar
Asada N, Kunisaki Y, Pierce H, Wang Z, Fernandez NF, Birbrair A, et al. Differential cytokine contributions of perivascular haematopoietic stem cell niches. Nat Cell Biol. 2017;19:21423.
CAS PubMed PubMed Central Article Google Scholar
Garca-Castro J, Balas A, Ramrez M, Prez-Martnez A, Madero L, Gonzlez-Vicent M, et al. Mesenchymal stem cells are of recipient origin in pediatric transplantations using umbilical cord blood, peripheral blood, or bone marrow. J Pediatr Hematol/Oncol. 2007;29:38892.
Article Google Scholar
Rieger K, Marinets O, Fietz T, Krper S, Sommer D, Mcke C, et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol. 2005;33:60511.
CAS PubMed Article Google Scholar
Nicolay NH, Perez RL, Saffrich R, Huber PE. Radio-resistant mesenchymal stem cells: Mechanisms of resistance and potential implications for the clinic. Oncotarget. 2015;6:1936680.
PubMed PubMed Central Article Google Scholar
Alessio N, Del Gaudio S, Capasso S, Di Bernardo G, Cappabianca S, Cipollaro M, et al. Low dose radiation induced senescence of human mesenchymal stromal cells and impaired the autophagy process. Oncotarget. 2015;6:815566.
PubMed Article Google Scholar
Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer. 2011;11:96110.
CAS PubMed PubMed Central Article Google Scholar
Sugrue T, Lowndes NF, Ceredig R. Mesenchymal stromal cells: radioresistant members of the bone marrow. Immunol Cell Biol. 2013;91:511.
CAS PubMed Article Google Scholar
Preciado S, Muntin S, Rico A, Prez-Romasanta LA, Ramos TL, Ortega R, et al. Mesenchymal stromal cell irradiation interferes with the adipogenic/osteogenic differentiation balance and improves their hematopoietic-supporting ability. Biol Blood Marrow Transplant. 2018;24:44351.
PubMed Article Google Scholar
Nicolay NH, Rhle A, Perez RL, Trinh T, Sisombath S, Weber KJ, et al. Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Lett. 2016;374:7584.
CAS PubMed Article Google Scholar
Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC, et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia. 2006;20:32935.
Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |…
Bacterial culture and growth conditions
A multidrug-resistant clinical strain of V. cholerae stored in the collection of the Bacteriology Department of Tarbiat Modares University, Tehran, Iran, was used. The strain was resistant to tetracycline, ciprofloxacin, chloramphenicol, cotrimoxazole, and trimethoprim. The bacterial culture was performed in 1mL brain heart infusion (BHI) broth (Merck, Germany) at 37C until reaching the log phase. The bacterial suspension concentration was determined by measuring the absorbance at 540nm and comparing it with the standard 0.5 McFarland optical density (OD). According to the growth curve, the bacterial suspension with an OD of 1:0 (~108CFU/mL) was used21.
Bone marrow-derived mesenchymal stem cells (BM-MSCs) and Caco-2 cells were purchased from the Iranian Biological Resource Center and Pasteur Institute of Iran, respectively. BM-MSCs were confirmed by assaying the differentiation of the cells into osteoblasts and adipocytes using an immunohistochemistry (IHC) assay. BM-MSCs were also characterized using the flow cytometry method for CD34, CD45, CD44, and CD73 markers18.
BM-MSCs were cultured in lowglucose Dulbecco's modified Eagles medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA) and 1% penicillin/streptomycin (Gibco, USA) at 37C in a humidified atmosphere containing 5% CO2. The medium was replaced after every 2days. A total of 5105 cells were seeded in a T75 flask (SPL, Korea) containing 15mL of DMEM supplemented with 10% FBS. When the confluency of the cells was near 90% at passage 2, the medium was replaced with serum-free DMEM. Subsequently, MSC CM was collected and centrifuged at 4000rpm for 30min and finally stored at 80C until use22. According to our previous study, chitosan nanoparticles were synthesized, characterized, and loaded with the supernatant of mesenchymal stem cells23. At all stages of this study, mesenchymal stem cell conditioned media (MSC CM; 1000g), chitosan nanoparticles incorporated with mesenchymal stem cell conditioned media (MSC CM-CS NPs; 1000g+0.05%), and chitosan nanoparticles (CS NPs; 0.05%) were used.
Vibrio cholerae cell suspensions were inoculated (1:100 dilution) into 1mL BHI broth medium containing 0.05% sucrose. The bacterial suspension was inoculated with MSC CM, MSC CM-CS NPs, and CS NPs overnight at 37C to evaluate the expression of biofilm genes. After this time, each well was washed three times with PBS, and adherent cells were harvested to evaluate the expression of biofilm-related genes. PBS and V. cholerae without exposure to the compounds were used as negative and positive controls, respectively. Each assay was performed in triplicate.
Caco-2 cells were cultured in DMEM supplemented with 10% FBS, 1% l glutamine (DNA Biotech, Iran), and 1% penicillin/streptomycin and incubated at 37C with 5% CO2. The culture medium was changed every two days, and when the confluency reached 80%, the cells were passaged. Since cells in monolayer culture with full confluency can form polarized cells while maintaining cell surface molecules, we explored cells at 85% confluency for all experiments24.
Caco-2 cell viability was estimated by the conventional MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. This was tested to evaluate the viability of Caco-2 cells after the exposure time to bacteria, MSC CM, MSC CM-CS NPs, and CS N. Briefly, 2({10}^{4}) Caco-2 cells per well were seeded into a 96-well plate and cultured for 24h at 37C. The medium was removed, and the cells were exposed to bacterial suspension (10 bacteria per epithelial cell; MOI: 10), MSC CM, MSC CM-CS NPs, and CS NPs separately for 24h. To assess cytotoxicity, a separate test was also performed for 72h. After these times, the medium was removed, and MTT solution was added for 3h at 37C. Then, the formazan crystals formed in cells were dissolved in 100L of dimethyl sulfoxide (Sigma Aldrich, USA). The resulting purple solution was measured using an ELISA reader (OD 540nm) (800 TS, BioTek, Winooski, Vermont, USA). Each assay was performed in triplicate25.
For this purpose, five groups were designed: (i) untreated Caco-2 cells (negative control); (ii) Caco-2 cells incubated with V. cholerae (MOI: 10-positive control); (iii) Caco-2 cells+V. cholerae+MSC CM; (iv) Caco-2 cells+V. cholerae+CS NPs; and (v) Caco-2 cells V. cholerae+MSC CM-CS NPs. Caco-2 cells were cultured in 96-well microplates until they reached 80% confluence. Before treatment, cells were washed three times with PBS. Then, the cells were infected with V. cholerae for 1h, and the extracellular bacteria and medium was removed and replaced with DMEM-free compounds, including 100L of MSC CM, MSC CM-CS NPs, and CS NPs, for 18h at 37C. After this time, the supernatant were removed, and then Caco-2 cells were used for total RNA extraction. Each test was performed in triplicate.
Total RNA from bacteria and Caco-2 cells was extracted using an RNA Miniprep Super Kit (Bio Basic, Canada) according to the manufacturers recommendations. The RNA was assayed by absorbance at OD260/280. Samples with a ratio of 1.82.0 were used for cDNA synthesis using Yekta Tajhiz Azma, Iran. According to the protocol, template RNA (5L), random primer (0.5L), and DEPC-treated water (7.5L) were mixed, centrifuged briefly, and incubated for 5min at 70C. Then, 5 first strand buffer (4L), dNTPs (1L), RNase 40U/L (0.5L), and M_MLV (1L) were mixed and incubated for 60min at 42C, and the reaction was terminated by heating for 5min at 70C. The cDNA samples were stored at 20C until use in the following experiment.
Conventional SYBR Green-based real-time PCR was used for target gene quantification. Real-time PCR was performed by using 10L 5 Real-time PCR Master Mix (Biomake, Houston, TX, USA), 1L of each primer (Table 1), 2L of cDNA, and 6L of distilled water in a total reaction volume of 20L in Stratagene Mx3000P real-time PCR system (Stratagene, La Jolla, CA). 16S rRNA was used as an endogenous control to normalize the expression levels of target genes of V. cholerae. Beta-actin was also utilized as an internal control to normalize the expression levels in RNA samples from Caco-2 cells. The CT of each sample was measured (CT targetCT reference). We used Caco-2 cells not treated as a calibrator, and the CT method was used to determine the difference between treated cells and the control. The fold change of gene expression level was calculated using the comparative CT (2CT).
The data were analyzed by using GraphPad Prism version 6 using one-way ANOVA and Bonferroni post hoc test. P value<0.05 was accepted as significant. The results of replications were also evaluated as the meanstandard deviation (SD).
The study was reviewed and approved by the Medical Ethics Committee of Tarbiat Modares University (Code: IR.MODARES.REC.1398.060). All methods were also carried out in accordance with the guidelines and regulations related to the committee.
See the original post here:
Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |...
Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -…
Global Cord Stem Cell Banking Marketreport aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Effortlessness maintained in research method and application of best tools and techniques makes this market research report an outstanding. The report is bifurcated into several attributes which include manufacturers, region, type, application, market status, market share, growth rate, future trends, market drivers, opportunities, challenges, emerging trends, risks, entry barriers, sales channels, and distributors which are again detailed in the universal A business report as required to describe the topic and provide maximum information for better decision making.
The key research methodology employed here by DBMR team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary validation. It has been assured that this business report makes available absolute knowledge and insights to the clients about the new regulatory environment which suits to their organization. The winningCord Stem Cell Banking Marketbusiness report helps clients recognize new opportunities and most important customers for their business growth and increased revenue.
With the resourceful use of technology, innovative applications, and expertise,Cord Stem Cell BankingMarket analysis report is built which successfully manages large and complex market data tables. The market report is produced based on the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. Not to mention, gathered market data and information is represented very well in the persuasive Cord Stem Cell Banking Market report with the help of graphs, charts or tables to simplify the flow for better user understanding. Market share analysis and key trend analysis are the two other major success factors of this influential market survey report.
Get a Sample PDF of the Cord Stem Cell Banking Market report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cord-stem-cell-banking-market
The cord stem cell banking market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 22.2% in the above-mentioned forecast period. Increase in the number of parents storing their childs cord blood drives the cord stem cell banking market.
Cord stem cells banking is defined as the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.
Global Cord Stem Cell Banking MarketScenario
According to Data Bridge Market Research the market for cord stem cell banking is booming with the rising expenditure in the healthcare solutions. The increment in the novel advancement for creating good and efficient drugs to cure unmet medical challenges for the betterment of public and patients health will deliver a strategic business growth for cord stem cell banking market globally.
The rising demand of cord stem cells by pharmaceuticals enterprises has arranged an ascending array of rise in the cord stem cell banks. This significant germination will be backed by the collection placentas of new born babies after their delivery. The stem cells procured from this source are capable of regenerating advanced cells. They help in transplantation of hematopoietic stem cell, the rate of transplantation is high so thus the requirement. These inputs yields in the graphical success of cord stem cell banking market will be visible in the forthcoming period of 2019 to 2026. Few of the factors will stand in between to hinder the market growth such as high end cost of the preservation and storage of cord stem blood cells, whereas the lower rate of familiarity among the pregnant population will affect its growth.
Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth in North America due to large healthcare infrastructure and leading investment in the cord blood cells research to generate stem cells.
For more analysis on the cord stem cell banking market request for a briefing with our analystshttps://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market
Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019
In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.
Cord Stem Cell Banking MarketScope
Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.
Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.
To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market
Increased acceptance of stem cell therapeutics is the vital factor escalating the market growth, also rise in the new applications of stem cells indiseasetreatment, rise in the spending on the management of chronic diseases, rise in the growth in awareness about stem cell therapeutics and increase in the mergers and acquisitions by prominent players are the major factors among others driving the cord stem cell banking market. Moreover, rise in the technological advancements and modernization in the healthcare devices and risingresearch and developmentactivities in the healthcare sector will further create new opportunities for cord stem cell banking market in the forecasted period of 2021-2028.
However, high operating cost of stem cell therapeutics and lack of awareness in many developing economies are the major factors among others which will obstruct the market growth, and will further challenge the growth of cord stem cell banking market in the forecast period mentioned above.
The cord stem cell banking market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cord stem cell banking market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth
Key Market Competitors Covered in the report
CBR Systems, IncCordlifeCells4Life Group LLPCryo-Cell International, Inc.Cryo-Save AGLifecellStemCyte India Therapeutics Pvt. LtdViacordSMART CELLS PLUS.Cryoviva IndiaGlobal Cord Blood CorporationNational Cord Blood ProgramVita 34, ReeLabs Pvt. Ltd.Regrow Biosciences Pvt. Ltd.Americord Registry LLC.New York Blood CenterMaze Cord BloodAABBStem Cell CryobankNew England Cryogenic Center, Inc.
Cord Stem Cell Banking MarketScope and Market Size
The cord stem cell banking market is segmented on the basis of storage type, product type, service type, source and indication. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis ofstorage type, the cord stem cell banking market is segmented into private banks, hybrid banks and public banks.
Based onproduct type, the cord stem cell banking market is segmented into cord blood, cord blood and cord tissue.
Based on service type, the cord stem cell banking market is segmented into collection & transportation, processing, analysis and storage.
Based on source, the cord stem cell banking market is segmented into umbilical cord blood, bone marrow, peripheral blood stem and menstrual blood
The cord stem cell banking market is also segmented on the basis of role of administration into cerebral palsy, thalassemia, leukemia, diabetes and autism.
Browse the complete table of contents at Cord Stem Cell Banking Market https://www.databridgemarketresearch.com/toc/?dbmr=global-cord-stem-cell-banking-market
Cord Stem Cell Banking MarketCountry Level Analysis
The cord stem cell banking market is analysed and market size insights and trends are provided by country, storage type, product type, service type, source and indication as referenced above.
The countries covered in the cord stem cell banking market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cord stem cell banking market due to rise in the presence of major market participants in the US, ongoing approval of stem cell lines for disease treatment, and increasing awareness among citizens in this region. Asia-Pacific is the expected region in terms of growth in cord stem cell banking market due to rise in the older population along with as surge in prevalence of chronic diseases, and rising per capita healthcare expenditure in this region.
The country section of the cord stem cell banking market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The cord stem cell banking market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for cord stem cell banking market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cord stem cell banking market. The data is available for historic period 2010 to 2019.
Key Pointers Covered in the Cord Stem Cell Banking MarketIndustry Trends and Forecast
Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study
Key Pointers CoveredMarket SizeMarket GrowthTop to Bottom Market AnalysisMarket SegmentedRecent Developments for Market CompetitorsRecent Market Value for Different CountriesMarket Value and OverView of this MarketCompany Profiling of Players of this Market
Why buy this report?
The report offers a comprehensive evaluation of the Global & Regional Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes an in-depth market analysis using Porters 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.The report also contains the competitive analysis using Positioning Quadrants, the analysts Proprietary competitive positioning tool.
Market highlights:Assessment of the marketPremium InsightsCompetitive LandscapeCOVID Impact AnalysisHistoric Data, Estimates and ForecastCompany ProfilesGlobal and Regional Dynamics
Key Questions Answered in the Market Report
How did the COVID-19 pandemic affect the reception of by different statistical surveying and life sciences organizations? What is the viewpoint for the effective market during the conjecture time frame? What are the key patterns affecting the effect market? How might they impact the market in short-, mid-, and long-haul length? What is the end clients insight toward? What are the key variables affecting the effect market? What will be their effect in the short-, mid-, and long-haul term? What are the key open doors regions in the effect market? What is their possible in short-, mid-, and long haul length? What are the key systems taken on by organizations in the effect market? What are the key application regions of the effect market? Which application is supposed to hold the most noteworthy development potential during the gauge time frame? What is the favored sending model for the effect? What is the development capability of different arrangement models present on the lookout? Who are the key end clients of this statistical surveying quality? What is their separate offer in the effect market? Which territorial market is supposed to hold the most noteworthy development potential in the effect market during the conjecture time frame? Which are the central members in the effect market?
Report Coverage-The report involves data triangulation based on top-down and bottom-up approaches.The report contains details on revenues, growth rate, strategies, etc.The report highlights market and technological trends, new product developments, etc.The report elucidates the data gathered from interviews with reputed stakeholders such as product managers, C-level executives, among others, operating in the market.The report also highlights the impact of COVID-19 and suggests measures and strategies to grow in the approaching years.
Top DBMR Healthcare Reports:
Read the original:
Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -...
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 – GuruFocus.com
REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. ( JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. Pacific Time. This years meeting is a virtual stockholder meeting conducted exclusively via live audio webcast on the Internet at https://www.cstproxy.com/JasperTherapeutics/2022. As described in the proxy materials previously distributed, stockholders of record at the close of business on April 26, 2022 are entitled to participate and vote at the 2022 Annual Meeting. To participate, stockholders will need to enter the 12-digit control number included in the proxy materials delivered to such stockholders.
Information about the virtual meeting webcast and instructions for how stockholders can participate in the 2022 Annual Meeting are included in the definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022 and are available on the InvestorsFinancials & Filings section of Jasper Therapeutics website at http://www.jaspertherapeutics.com or the website for the 2022 Annual Meeting at https://www.cstproxy.com/JasperTherapeutics/2022.
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective, and potentially curative, allogeneic hematopoietic cell transplants and gene therapies. A clinical study of JSP191 as a novel, disease-modifying, therapeutic for patients with lower risk MDS is also planned to begin in 2022. In parallel, Jasper Therapeutics, Inc. is advancing its preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.
Contacts:
John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]
Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]
Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -…
MarketQuest.biz has announced the addition of new research titled Global Rheumatoid Arthritis Stem Cell Therapy Market from 2022 to 2028, which encompasses regional and global market data and is predicted to generate attractive valuation.The Rheumatoid Arthritis Stem Cell Therapy research covers market drivers, opportunities, limiting factors, and barriers. It provides a quantitative market study based on annual reports, product literature, industry announcements, and other sources.
The report explains the market definition, classifications, applications, engagements, and global Rheumatoid Arthritis Stem Cell Therapy industry trends are.It gives a realistic picture of the current market position incorporating original and predicted market estimates.The report gives a thorough analysis of their product portfolios to investigate the products and applications they focus on while working in the worldwide Rheumatoid Arthritis Stem Cell Therapy market. The report offers valuable suggestions to new just as set up players of the market.
DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/121261
In order to improve industrial planning, data points such as flow patterns, openings, drivers, limits, and statistics are acquired from trusted sources. The data and numbers in the research report have been provided comprehensively, using graphical and pictorial representations to understand the market better.Further when datais synthesised, statistical analysis takes place. Several processes, including screening, integration, and data extrapolation, must be performed prior to data validation.
The product types covered in the report include:
The application types covered in the report include:
The countries covered in the market report are:
The key and emerging market players in the global market include:
ACCESS FULL REPORT: https://www.marketquest.biz/report/121261/global-rheumatoid-arthritis-stem-cell-therapy-market-2022-by-company-regions-type-and-application-forecast-to-2028
Significance of The Report gives the idea about thebroad and precise understanding, industry drivers and challenges affecting the industry growth, planning the business strategies and factors leading to the market development, and evaluating the market competition and planning
Customization of the Report:
This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.
Contact UsMark StoneHead of Business DevelopmentPhone: 1-201-465-4211Email: sales@marketquest.biz
Stem Cell Transplant the only curative treatment for Sickle cell Disease – NewsPatrolling
World Sickle Cell Day 2022:
Bangalore, June 16, 2022: There are as many as 2.5 million carrier of the gene (Hemoglobin AS) in India that can lead to sickle cell disease, with more than 1,25,000 actual patients spread across the country, with a much higher incidence in the tribal belt of the country. Sickle cell disease is associated with a significant risk of morbidity and premature mortality, especially among children. While in the west, a child receiving comprehensive care in high-resource settings has an estimated 99% survival into adulthood. However, in India, according to an ICMR study, about 20 per cent of children with sickle disease died by the age of two, and 30 per cent children with Sickle Cell Disease die before they reach adulthood.
Dr. Biju George, Professor & Head, Department of Haematology at CMC Vellore, People with Sickle Cell Disease, may beat a risk of progressive organ damage, impaired quality of life, considerable morbidity in childhood, and risk of premature mortality in adulthood [median survival of 58 years]. Sickle Cell disease patients who are undergoing regular life-long blood transfusions, have the best chance of survival and cure with a blood stem cell transplant. This transplant can come from a sibling or a family member. However, there is only a 30% chance of finding a matched sibling donor in the same family. The remaining 70% patients look for a matching donor through a stem cell registry or donor center- a database of voluntary donors between the age group of 18 to 50 years.
Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, If there is a fully HLA matched donor in the family, there is a 90-95% chance of cure with higher cure rates in younger children of below 12 years of age. However, due to underrepresentation of Indians in the global donor data pool, patients are unable to find a match on time. Also, the awareness about the disease is less, need of the hour is to raise the social awareness about this disease. Genetic counseling and newborn screening are the way forward. Effects of endogamy, consanguinity and role prenatal counseling needs to be addressed in primary screening.
DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and sickle cell disease. The organization aims to give every blood disorder patient in need a second chance at life.
To mark World Sickle Cell Day, Patrick Paul, CEO, DKMS BMST Foundation India said, Sickle cell has variance and only the severe form needs a stem cell transplant. An early transplant can help patient with severe Sickle cell disease from organ damage. With rising cases in India, it is the need of the hour that stem cell transplants are made available to more patients to save lives. But due to the misconceptions and lack of awareness about blood stem cell donation, Indians are highly underrepresented in the global donor pool. This situation can only be changed by recruiting many more potential blood stem cell donors from the Indian ethnicity.
The success of a stem cell transplant depends of donors HLA (Human Leukocyte Antigen) matching the patient. The bodys immune system has proteins known as HLA to distinguish cells that belong to the body from those that do not. DKMS-BMST helps in unrelated donor transplant process which includes enrolling and counselling the donors, get their HLA typing done, facilitate search of the donors and later facilitate the blood stem cell collection and the transplant. So, far DKMS-BMST has registered over 60,000 potential donors and have helped 60 patients with second chance at life.
Register as a potential blood stem cell donor:
Healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register
All it takes is five minutes of your time and a simple 3 step process:
Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home.
Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.
Step 3: Send back your swab sample in the pre-paid envelope provided.
DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.
Read more:
Stem Cell Transplant the only curative treatment for Sickle cell Disease - NewsPatrolling
STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD – StreetInsider.com
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
MIRAMAR, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that Charles Arnold, Stemtechs Chairman and CEO, has received the Global Eagles Business Leader of the Year award.
The award was presented at a ceremony in Fort Lauderdale, Florida by Global Eagles International Chairman the Honorable Randy Avon. The Global Eagles is a group of diplomats, investment bankers, CEOs, University Presidents, investors and top international executives who gather regularly to network, present global projects to a group of seasoned peers, and to promote best leadership practices.
I am truly honored to receive the Global Eagles Business Leader of the Year award, said Chuck Arnold, Chairman and CEO of Stemtech. The Global Eagles community is a distinguished group that includes top leaders in business, the investment community, government and academia. The impact that this organization and its members have had on international development and infrastructure is hard to overstate. I continue to enjoy the camaraderie and friendship of fellow Global Eagles members, and I look forward to being a member for many years to come.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed onMay 16th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investor Relations: Frank J. Pena, 908-675-0581,
[emailprotected]
Read the original here:
STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD - StreetInsider.com
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) -…
First Site Will Enroll First Patient in the Clinical Study
MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) BioRestorative Therapies, Inc. (the Company or BioRestorative) (NASDAQ: BRTX),a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.
BioRestoratives Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Companys autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
Currently there are no approved, cell-based therapies for cLDD. While there is encouraging data that suggests that patients with cLDD could benefit from autologous stem cell transplants, the low oxygen micro-environment of the disc makes cell-based therapies challenging. BRTX-100 is manufactured under low oxygen conditions and engineered to survive this environment, said Scott Bainbridge, M.D., Principal Investigator for the BRTX-100 trial at The Denver Spine and Pain Institute. Positive proof-of-concept data in this trial could be disruptive and support the potential applicability of BRTX-100 to other spine and musculoskeletal disorders where low oxygen micro-environments are found.
We are pleased to initiate the first of several sites across the United States that will be enrolling for the trial, said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. Our sites have been carefully reviewed and selected and have clinical expertise in treating patients who could potentially benefit from BRTX-100. We look forward to working with the principal investigators and their clinical trial teams.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Companys latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:Email:ir@biorestorative.com
Surgery gives teen opportunity to help other kids with cancer – Houston Chronicle
For every procedure Hallie Barnard has undergone at MD Anderson, she receives a bead. The yellow ones symbolize each night in the hospital. The ones that glow in the dark represent radiology appointments.
Theyre for every poke, every wound cleaning, every physical therapy appointment, the 13-year-old said.
MD Anderson launched its Beads of Courage program in 2008 so young patients could document their journeys through cancer treatment. Collecting colorful strings of beads also provides some incentive to show up at dreaded doctor appointments.
Hallie has more than 350 feet of beads.
They symbolize everything that Ive gone through in the past four years, the Denton resident said.
Still, Hallie is less concerned about her own struggles through osteosarcoma, a cancer that begins in the bones, than she is with shining a light on the challenges other children face.
Every time I show people my beads, it dawns on them that children are going through so much, she said. And there are children with longer beads than I have.
According to the American Childhood Cancer Organization, about 15,780 children are diagnosed with cancer in the U.S. each year.
Their studies indicate 1 in 285 children will be diagnosed with cancer before their 20th birthday and that cancer is the leading cause of death for children between the ages of 4 and 14 in the country.
Children are dying of cancer at astonishing rates, Hallie said.
Regardless, she said, childhood cancer research is underfunded. Less than 4 percent of the federal budget for cancer research is dedicated to its study, according to the Childrens Cancer Research Fund, a national nonprofit.
I dont want any of my friends to die anymore, Hallie said. I want to show them that I am there for them. I am their voice. I can speak for those who cannot speak for themselves.
Hallies Heroes, the nonprofit she started with her parents, Elyse and Jesse Barnard, helps fund childrens cancer research.
But thats not how it began. The organization was founded to inspire individuals to register as bone marrow donors. Because, at the time, Hallie was facing another seemingly insurmountable challenge finding a match for herself.
Hallie was diagnosed with Diamond-Blackfan anemia when she was 13 months old.
Your bone marrow is basically what makes your red blood cells, she said. And with DBA, that fails to happen, Hallie said.
Elyse said her daughter did not seem to be growing normally or hitting milestones at the right time during her first year of life.
Our pediatrician would tell me everything was OK, she said. As a first-time mom, we tend to worry about everything, but I knew that something was wrong.
That fear was validated when Hallie went for her 12-month checkup. A blood test revealed low levels of hemoglobin, and she was admitted to the hospital.
Diagnostics pointed to Diamond-Blackfan anemia but doctors were still skeptical due to the rarity of the disease, Elyse said.
In the end, Hallie had a diagnosis. But treatment options were even more elusive.
Only five to seven babies per million have Diamond-Blackfan anemia, according to St. Judes Research Hospital.
Blood transfusions and steroids can be used to manage symptoms, but both take a toll on the body, Elyse said.
Stem cell transplants offer the only possible cure. The issue is finding a donor.
Theres just a 1 percent chance of finding a match for bone marrow transplants, Hallie said.
Her family began looking and moved from Virginia to Texas, after learning that Dallas had one of the four hospitals in the U.S. specializing in the disorder.
Out of the Barnards search for donors, Hallies Heroes was born.
In the search for her own bone marrow donor, other matches were made. So far, there have been 184 and the organization has inspired more than 8,000 people to join the bone marrow registry.
To its mission, Hallies Heroes added funding for Diamond-Blackfan anemia research and covering medical bills.
Hallie found her own match for a bone marrow transplant when she was 9. The procedure was scheduled the following year, 2018.
She was in the hospital for 60 days, kept in isolation for the duration to protect her fragile immune system, which was wiped out by chemo.
After 100 days, the bone marrow transplant is usually considered fully integrated, Elyse said.
You basically do a happy dance, because you have a new immune system, she said. We thought we were in the clear.
But at 120 days, Hallie had a new symptom.
I started getting horrible pains in my leg, she said. We found a small bump, the size of a mosquito bite.
The growth was right above her left knee. Doctors told her to draw a circle around it to see if it grew.
In a week, it had doubled, Hallie said.
Diagnostics revealed the bump was indeed a tumor.
In March 2019, Hallie was diagnosed with osteosarcoma, a bone cancer that develops most often in children and young adults.
Hallie was presented with a few different choices. She could opt for an amputation or limb salvage surgery to remove diseased bone and replace it with a metal implant or a bone graft, called at allograft, from another person.
We wanted to get a second opinion, Hallie said. Our doctor said, I studied under this amazing woman, Dr. Lewis. Yall should go to MD Anderson.
Dr. Valerae O. Lewis serves as the inaugural chair of orthopedic oncology at the hospital. In fact, she created the Department of Orthopedic Oncology in 2014.
The Barnards made an appointment to see her in mid-April 2019.
Data from MD Anderson shows that between 800 and 900 cases of osteosarcoma are diagnosed annually in the U.S. About half of these are children and teens.
Lewis presented Hallie with three options. You can do an amputation, she began.
Historically, that was the only choice available to remove the tumor completely. But now there are additional options limb-salvaging surgery and rotationplasty, Lewis said.
Limb-salvaging surgery can be performed if the cancer has not metastasized.
Limb-salvage is a great option, because it gives kids the ability to keep their legs, Lewis said. But it does take a toll.
Patients activity levels are restricted and additional operations are needed down the road, probably every 15 to 20 years.
The third option, a rotationplasty, removes the tumor along with the middle part of the leg and the knee. The surgeon then rotates the lower leg 180 degrees before reattaching it to the thigh.
Its like an amputation, but we create a new knee, Lewis said.
Rotationplasty allows patients to be higher functioning. Its easier to walk, Lewis said. You can bike, skate and swim. Everything you need a knee for, you can do.
Hallie chose rotationplasty. Surgery was scheduled for late June 2019, and she had chemo before and after surgery.
She was 11 at the time and had complications while healing, including infections. She needed a wound vacuum for about 11 months. When Hallie finished chemo in 2020 in Fort Worth, her bones had not yet fused.
Then, Dr. Lewis came up with a genius idea, Hallie said.
Lewis inserted a titanium rod into the nonhealing site to help.
Hallie said that Lewis restored her confidence.
Theres a point when a patient gives up. And theres also a point when a doctor gives up. She said that she had not given up on my leg yet, Hallie recalled.
After rotationplasty, a prosthesis is worn, and patients have to relearn how to walk.
Even though the ankle now functions as the knee, it is entirely different from the typical configuration, Lewis said.
The foot fits into the prosthesis, she said. And one needs to remember that it is a functional foot interfacing with the prosthesis.
The toes can provide balance and aid in powering the prosthesis, Lewis added. The plantar surface also allows for bearing weight.
Hallie was at MD Anderson for about seven months, working on both physical and occupational therapy, until she headed back to Denton April 8.
Hallie has progressed nicely and is walking distances without support, Lewis said.
With further physical therapy and continued dedication she anticipates Hallie will be running, skipping and jumping in the future.
Hallies follow-up appointments at MD Anderson are scheduled every three months.
When Hallie was first diagnosed with osteosarcoma, she remembers telling her mother, God put me back in the hospital to help other children.
Now she advocates for both children with cancer and those with Diamond-Blackfan anemia.
At one point, while Hallie was healing from surgery, Elyse and Jesse went to a wall where donors names are displayed on the ninth floor of MD Anderson.
Every day, her dad and I passed the wall, Elsye said. One day, she wanted to see Hallie added to the names.
After changing the bylaws of the nonprofit, Hallies Heroes pledged $50,000 over five years in support of Lewis research in the area of pediatric sarcoma.
Hallie went on the wall in November.
It was really cool to come full circle with that, Elyse said. We were once there as parents, not knowing if our child would survive and seeing all the people donate money so that she could.
Now were giving back, because we want other children to survive, she added.
The funding will make a significant impact, Lewis said, and will go toward researching treatments for pediatric sarcoma.
Hallie is a success story, Lewis said. She is our ambassador and is a cheerleader to other patients. She wants to give back and help other kids like her.
Peyton is a Houston-based freelance writer.
Read the original post:
Surgery gives teen opportunity to help other kids with cancer - Houston Chronicle
Anadrole Reviews – Best Alternative to Anadrol Steroid? Any Side Effects? – MarylandReporter.com – MarylandReporter.com
Anadrole Reviews Does CrazyBulks Anadrole (Anadrol) Supplement Really Work? Do the ingredients have any negative side effects? Read its price, results, dosage & customer reviews!
Official Website: Click Here
What is Anadrole?
Anadrole is a muscle-building supplement developed by CrazyBulk that imitates the effects of the anabolic steroid Anadrol and androgen oxymetholone, which treat low levels of red blood cells.
Its primary function is to stimulate the synthesis of red blood cells in your body, which in turn helps to reduce the symptoms of anemia, including lethargy, muscle weakness, and weariness, among other symptoms.
Anadrole from CrazyBulk contains high concentrations of various proteins, amino acids, and ergogenic herbs.
These ingredients all work together to produce the same results as oxymetholone without harming your health.
It is designed to offer all of the advantages that its equivalent, available only by prescription, does, but without any potentially harmful effects.
Because the steroid Anadrol increases your stamina and assists you in fighting exhaustion, the Anadrole supplement makes it possible for you to attain bigger improvements in muscle mass.
It can effectively assist in growing muscle and bolstering muscle strength, and it speeds up the healing of muscles after exercise.
Your workouts will be more effective if you include them in your routine, and it is simple to use Anadrole in any fitness program.
Improve your physical performance, maintain your muscle mass, and shed excess weight with the help of this cutting-edge muscle-building supplement Anadrole.
It provides sustained energy surges, enabling you to work better and for longer at the gym. As a result, you can break through muscle-building plateaus more easily.
You will be able to achieve your fitness objectives more quickly and easily if you consistently apply this powerful method.
Click to Learn More About the Anadrole on the Official Website
How does Anadrole supplement work?
It accomplishes this by utilizing two metabolic processes stimulated by its proprietary formulas. To begin, taking this Anadrole can enhance a process known as erythropoiesis, which takes place in the bone marrow.
To put it another way, the stimulatory impact that the capsules have on the bone marrow stem cells causes an increase in the creation of red blood cells.
Because of this increased RBC, more oxygen will be carried into organs, particularly the muscles.
As a consequence, the muscles may be able to recover from weariness more quickly.
The second impact is known as the androgenic effect, which plays a role in both the manufacture of testosterone and the improvement of the bioavailability of male hormones.
Testosterone plays a significant role in the initiation of fat burning, which is beneficial to the process of creating lean muscle.
Click to Learn More About the Anadrole Supplement
Benefits of consuming Anadrole Capsules:
The Anadrole supplement sold by CrazyBulk is comprised of a potent composition that helps maintain your muscle health in a variety of ways.
Shocking New Anadrole Report: This May Change Your Mind
What are the Ingredients used in Anadrole Supplement?
Anadrole has appropriate quantities of natural substances that improve muscle strength, growth, and recovery and is packed full of these nutrients.
They cooperate to alleviate the symptoms associated with iron deficiency and low numbers of red blood cells.
In light of scientific research, the following is everything you need to know about the components that are found in Anadrole and the benefits that come from them:
Tribulus Terrestris, a plant native to the Mediterranean region that bears fruit and is a member of the caltrop family, is traditionally employed in herbal medicine as an aphrodisiac.
It is loaded with compounds that improve sexual performance in both men and women and has these substances in plenty.
The compounds found in the fruit of the Tribulus Terrestris plant have the power to interfere with the function of particular hormones in your body beneficially, which results in the production of ergogenic effects.
Anadrole from CrazyBulk has a total of 500 mg of Tribulus Terrestris fruit extract packed into every serving.
Soy protein is a type of protein that can be acquired from soybeans. It is unique in that it contains all of the essential amino acids your body cannot produce independently.
Because it is a complete protein, it stimulates muscle protein synthesis in your body by supplying your body with significant quantities of all of the required amino acids.
Losing weight, maintaining good cholesterol levels, and gaining muscle are all benefits. The Anadrole sold by CrazyBulk includes 200 mg of soy protein extract in every serving.
Whey protein, the primary protein found in dairy products, encourages the development of new proteins within your body by providing it with all of the needed amino acids.
It is a protein that is broken down very quickly and is an essential component in the process of creating new muscle protein.
Anadrole sold by CrazyBulk comes with 200 milligrams of whey protein concentrate in every single serving.
Nitric oxide can be produced from the amino acid L-arginine when it is metabolized in the body.
L-arginine has a role in maintaining healthy blood flow by contributing to the production of nitric oxide, which is important for keeping your blood vessels relaxed.
In addition, it influences particular hormones in your body, such as insulin and growth hormone, amongst others.
L-carnitine is a naturally occurring amino acid derivative that aids in synthesizing energy and enhances thermogenesis and encourages body fat reduction.
Your endurance will improve due to acetyl-l-role carnitine in the mitochondria, and you will be able to push yourself further during your workouts.
Acetyl l-carnitine is the primary factor responsible for Anadroles capacity to increase ones energy levels. Anadrole sold by CrazyBulk contains 50 mg of acetyl l-carnitine in every serving.
Shocking Results of This Anadrole Supplement Reported!
Pros of Anadrole:
Cons of Anadrole:
Check Out Anadrole Supplement Reviews From Real-Life Customers
Side effects of Anadrole Crazy Bulk
Anadrole does not contain an API, which stands for active pharmaceutical ingredient, or, to put it another way, the chemical compound responsible for carrying out all of the necessary functions.
The so-called beneficial effects are caused by certain herbs and the extracts of those herbs, similar to the way that Ayurvedic medications and other traditional treatments function.
Because you are genuinely consuming certain plant components in capsule form, there are no adverse consequences, unlike those caused by steroids, such as kidney failure, liver damage, high blood pressure, or organ damage.
Click to Order Anadrole Steroids From the Official Website (60 Days Money-Back Guarantee)
Pricing of Anadrole and Return Policy
One bottle of CrazyBulks Anadrole costs $64.99 and includes 60 individual capsules in each bottle.
If you buy two bottles at once, you will receive a free bottle as a bonus, and the total cost of 3 bottles is $129.98.
When you place an order straight through the official CrazyBulks Anadrole supplement website, you get free shipping on all of your purchases, no matter where you are.
Check Current Anadrole Supplement Pricing & Discounts!!
How to use Anadrole?
To experience the maximum potential of Anadrole, the manufacturer suggests taking two capsules each day for at least two months.
Because it requires the body a little bit more time to digest it, it is recommended that the Anadrole be taken first thing in the morning.
It is recommended that you take both capsules at the same time, at least twenty minutes before breakfast, to ensure that the Anadrole capsules are adequately absorbed along with the food.
When taking capsules, it is advisable to consume them with water or fruit juice; alcohol of any kind should be avoided at all costs.
The body is better able to properly distribute the tablets contents when it is given for 60 days consecutively followed by 10 days off cycle.
Click to Get the Best Deal on Anadrole from the Official Website
Anadrole Reviews Final Verdict
Anadrole is a great option for beginners and intermediates looking for a supplement that will help them gain muscle, increase their endurance and stamina, and improve their lean body mass.
This one, in contrast to other legal steroids, has a price tag that is slightly more reasonable, and its impact is comparable to that of the original steroid.
This products capacity to increase RBC counts assists in the fight against fatigue and shortens the time needed for recovery after exercise.
As a result of the herbal formulation, Crazy Bulk products do not cause any unfavorable health effects and do not cause any side effects.
Get Anadrole Now With Special Discount (Worldwide)!
Disclaimer: We are a professional product review website. We might receive compensation when you buy through our website, we may earn a small affiliate commission. The information contained on this website is provided for informational purposes only and is not meant to substitute for the advice provided by your doctor or other healthcare professional. The products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.
People also search for: anadrole reviews anadrole review anadrole crazy bulk review anadrole side effects anadrole crazy bulk anadrole vs anadrol anadrole crazy bulk side effects anadrole results anadrole ingredients
Continued here:
Anadrole Reviews - Best Alternative to Anadrol Steroid? Any Side Effects? - MarylandReporter.com - MarylandReporter.com
The gift of life: How stem cell transplant helped a flight attendant trump Cancer – The New Indian Express
Express News Service
CHENNAI: In 2004, flight attendant Kaveri Mandanna was battling frequent fevers, cold, and dipping haemoglobin. Life was an endless series of check-ups and blood transfusions. After consultations with a haematology specialist, tests and procedures ensued. Kaveri's condition was found to be leukaemia -- it meant that her bone marrow tissue was rapidly producing abnormal numbers of a certain type of blood cell, crowding out the others.
Although shaken, she didnt want to lose hope. "I had to be alive for my daughter -- that was the only thought pushing me to fight," says Kaveri who was in her 30s then.
A bone marrow transplant, also called a stem cell transplant, was recommended as a recourse. That gave Kaveri additional succour.
"Today, people suffering from rare diseases like certain types of cancer, sickle cell anaemia, immune conditions, and other conditions affecting the production of blood, have a shot at being cured through such stem cell transplants," says Dr G Buvaneswari, infertility specialist, Rela and GBR Hospitals.
Stem cells are special cells which can create copies of themselves. "These are the bodys raw cells -- they keep dividing and evolving into other cell types such as the bones, heart muscle, nerves, other organs and tissue," explains Dr Buvaneswari.
Its a matchThe tricky part of such transplants? Finding an immunologically compatible donor. As Kaveri had two siblings, who are natural genetic matches, they were HLA-typed.
Explaining this, Dr Buvaneswari says, "This procedure identifies protein markers on cells and tissues. The markers help determine whether or not a donor and a beneficiary match."
The more the markers, the fewer the risks of infection. To Kaveri's luck, her younger brother was found to be eligible to donate.
Uthappa, Kaveris brother and donor, was glad that he could potentially save his sister's life. However, he was apprehensive, too.
"Blood from one of my arms was collected every day, for five days, for a few hours. It was a smooth process, but, still, I was worried I'd experience side effects after giving away my stem cells," says Uthappa. But there was no cause for concern, he found, as donors are given injections to replicate extra bone marrow stem cells.
On D-day of the transplant process, Uthappa's stem cells were introduced into Kaveri's body via a catheter. Meanwhile, Kaveri had undergone chemotherapy which emptied her bone marrow of all its blood cells, including the healthy ones. This is done to make space for the donor's stem cells, says Dr Buvaneswari.
With time, the transplanted stem cells travelled to Kaveris bone marrow, where it started producing healthy red blood cells, white blood cells, and platelets of its own.
Kaveri still needed to do check-ups at regular intervals. "At first, I had to meet my specialists every week. Then, the frequency reduced to quarterly sessions, and later, once a year," Kaveri recounts. Subsequent signs of her cell count returning to the normal number indicated disease remission.
Almost six years later, from the day of the transplant in 2004, Kaveri's cancer was cured. "The transplant's success and the blessing of being declared cancer-free gave me the confidence to resume my globe-trotting life," she exclaims.
Banking for the futureWhile Kaveri was lucky enough to find a biologically-related donor, the odds in general are not quite high. Contacting a registry of voluntary unrelated donors is the only option then.Healthy individuals between the ages of 18 to 60 can register to donate their blood stem cells, says Sumati Misra, head, counselling and transplant centre management at DATRI blood stem cell registry. Having a wide pool of registered donors increases the odds of finding HLA matches for those needing transplants, she says.
"At DATRI, we have 1,800 patients registered with us who havent found a match yet from our registry of almost four lakh registered donors," shares Sumati.
Another factor in HLA typing is ethnicity, thus, it's hard to find a European registry match for an Indian. A large Indian donor registry solves that problem, she suggests.
Did you know that umbilical cord blood is a rich source of stem cells?
"The cord and the placenta, generally discarded as medical waste. They can be saved, and the stem cells from the tissue and the blood extracted, and stored for future transplant use," says Dr Buvaneswari.
As the blood is tested for infections, the likelihood of a person's body rejecting stem cells from cord blood is lesser than from bone marrow.
Some parents pay for their children's cord blood cells to be cryo-preserved in private banks for an extended period of time. They can be used in the rare event of a child developing a condition, in the future, that can be treated with stem cell therapy. The child's siblings stem cells, too, if they are HLA matches, can prove helpful.
"If the child is found to be an HLA match with another child, alternatively, parents can take a call on donating the banked cord blood. As cord blood banking is an expensive undertaking, donating them may be ideal," suggests Dr Buvaneswari.
Research on stem cells is underway to see if they can treat various conditions that affect different systems and parts of the body. Stem cell therapy could be a prospective game-changer in not just regenerating tissues but also organs, says Dr Buvaneswari, who is currently researching the use of stem cells in infertility treatment.
Sharing a recent trend from the field, the doctor says, "After pre-clinical trials with animals, it was observed that stem cell therapy could restore their ovarian and even testicular functions."
"After more phases of the trials with human cells, the results, if favourable, could lead to advancements in reproductive care," she concludes.
Follow this link:
The gift of life: How stem cell transplant helped a flight attendant trump Cancer - The New Indian Express
How Does Stem Cell Transplant Work In Thalassemia? Know Everything | TheHealthSite.com – TheHealthSite
Thalassemia is an inherited blood disorder that cannot be treated with medication. But stem cell therapy may be able to help. Know if stem cell therapy will work for the disease.
Written by Editorial Team | Updated : May 18, 2022 10:56 AM IST
Haemoglobin is the oxygen-carrying protein in the blood. In the absence or reduced amount of haemoglobin, the red cells do not survive for a long period and there is a diminished oxygen supply to the tissues causing a variety of symptoms. Thalassemia is an inherited blood disorder in which there is less haemoglobin than normal. There are two parts to the haemoglobin molecule alpha and beta. The disease is named based on the subunit that is not being made by the body alpha or beta-thalassemia.
Thalassemia runs in families; however, not everyone who has a dysfunctional gene for haemoglobin will have the symptoms of the disease. Those with moderate-severe disease experience symptoms such as breathlessness, weakness etc. (symptoms of anaemia), all associated with low levels of oxygen, from childhood. However, those with the mild disease might incidentally be diagnosed with thalassemia, mostly during investigations for other conditions or for anaemia.
Unfortunately, thalassemia cannot be prevented. Patients with the severe disease receive frequent blood transfusions, in an attempt to replenish a pool of healthy red blood cells. However, this procedure is associated with several issues such as iron overload that can deposit in different organs over time, immune system reactions, and risk of blood-related infections such as hepatitis, HIV etc. Folic acid is also prescribed to patients, which can help in the development of red blood cells.
Considering the issues with the conventional treatment of thalassemia, stem cell therapy can be an attractive choice for the condition. Allogeneic hematopoietic stem cell (blood stem cells) transplantation has been considered the only curative treatment for thalassemia. This treatment works by replenishing a healthy pool of blood-forming stem cells (master cells of the body) in the bone marrow consider the bone marrow as a factory of stem cells and specialized blood and tissue forming cells. However, considering that the source of stem cells is from a donor (usually a first-degree relative) because a patient's own blood-forming stem cells would be affected by the genetic mutation there are chances of certain side effects. One way to manage these issues is by the use of mesenchymal stem cells, which are known to have immune system regulating properties. By this, the rejection-related issues with hematopoietic stem cells as well as reduced immunity-related side effects can be handled efficiently. Considering that thalassemia is a disease that affects blood cells, mesenchymal cells (tissue forming cells) from the patient's own body are not affected.
Through this combined approach, a patient can achieve long-term remission from the symptoms of thalassemia without side effects. "Stem cell therapy for thalassemia is not a new treatment, only the approach by using a combination of stem cells to achieve holistic outcomes is novel.
(The article is contributed by Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd., Navi Mumbai/Mumbai)
Follow us on
What’s New in Equine Orthobiologics? The Horse – TheHorse.com
Named for their ability to branch out to become cells that build multiple kinds of tissue, mesenchymal stem cells (MSC) and mesenchymal stromal cells appear in embryos and adult bone marrow, respectively. In 2019 scientists suggested redefining the MSC acronym as medicinal signaling cells, because the therapeutic cells usually come from bone marrow rather than the mesenchymea part of embryos. In this article well refer to all these similar cell types as stem cells.
Twenty years ago biologists had successfully developed stem cells into cartilage, tendon, heart, bone, and other kinds of tissues in their laboratoriesspurring hope for unprecedented tissue repair therapies in humans and animals.
Scientists now know stem cells use a very different healing mechanism than previously suspected, Oosterlinck says. In fact, recent research has revealed its not what these cells become that matters, but what they doand, more specifically, how they do it, in large part through a process known as paracrine signaling.
Basically, theres a lot of crosstalk that happens between stem cells and the injured cells, Schnabel says. That crosstalk seems to recruit special cells within the injured tissue called progenitor cellsand those appear to develop into the original local tissue cells, such as tendon cells.
Some research groups are looking at ways to predifferentiate cells in a laboratorypreparing them to go into tendon versus cartilage tissue, for exampleto help encourage them to be more effective in their therapeutic environment, Oosterlinck says.
Meanwhile, other research teams are showing how stem cells trigger specific cytokines (cell-signaling proteins) and growth factors that contribute to better tissue healing, he says.
The cells also encourage vascularization, says Schnabel. They actually bring blood vessels into the area, promoting angiogenesis, she says.
These recent discoveries about stem cell functions are major breakthroughs, says Schnabel. Her team currently focuses on optimizing the use of these cells. One thing theyre homing in on is dosing, which has always been complex, especially in horses, because its impossible, she says, to achieve the per-pound dose of cells recommended in human medicine.
Theyre also fine-tuning the question of treatment timing, she says. Traditionally, clinicians have treated horses with stem cells once the initial inflammatory response from the injury subsides. The idea was that you dont want to cause more inflammation, potentially, and have an even lamer horse, and you dont want the stem cells to get killed by the inflammation, she explains.
Ultimately, that might not be the right approach. All the studies weve been doing actually suggest the opposite, that having them in an inflammatory environment is good, because it further primes the cells to secrete the things you want, she says.
Then that also begs the question, if you get a horse after the time of acute inflammation, could you prime the cells first in the lab so that theyre ready to go when you put them in the horse? she adds. And thats been a major focus of our work. We have a lot of strong preliminary data suggesting that thats true.
Schnabels team, as well as other research groups, have looked specifically at tendon healing, revealing that horses treated with stem cells have significantly reduced re-injury rates, especially in the superficial digital flexor tendon (SDFT)which has a traditional re-injury rate of up to 70% in racehorses (RK Smith, et al.). This is huge, she says.
See more here:
What's New in Equine Orthobiologics? The Horse - TheHorse.com
Cell Therapy Market Status and Size Report 2030 The Daily Vale – The Daily Vale
Theglobal cell therapy marketsize was valued atUSD 8.1 billion in 2021and is estimated to reachUSD 23.9 billion by 2030, growing at a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cellular therapies in context to their efficiency & manufacturing are expected to be major drivers for the market. Moreover, the development of stem cell banking facilities and resultant enhancement of stem cells production, storage, and characterization are also expected to improve the volumetric capabilities of the market at a global level, which is anticipated to directly translate into revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for stem and non-stem cells usage are expected to reinforce the demand over the forecast period. There are fewer commercialized cellular therapy products in the current market than the number of research products. This is partly due to stringent regulations and the high cost of stem cells.
Cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized as having high growth potential; as a result, many research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.
Pricing of stem cell transplantation varies from region to region. For instance, the cost of transplantation in the U.S. is higher than that in Germany or China. In March 2018, Alofisel by TiGenix received approval for marketing in Europe. This was the first allogeneic stem cell therapy to be approved in Europe. Furthermore, revenue for certain products varies for the country; for instance, products like INVOSSA received approval for marketing in Korea but have yet to receive marketing authorization in the U.S. Growth is also influenced by the commercialization of unauthorized stem cell treatments revenue generation.
Get PDF for more Professional and Technical insights:https://www.marketstatsville.com/request-sample/cell-therapy-market
Global Cell Therapy Market Definition
Therapy in which viable cells are injected, grafted, or implanted into a patient to effectuate a medicinal effect is known ascell therapy; for instance, In immunotherapy, T-cells capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissues.
Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and their clinical translation. Rapid advances in stem cell research have the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. Several unknown therapies are in clinical development.
Furthermore, government and private funding agencies are constantly offering grants to support projects at various stages of clinical trials, increasing the number of ongoing clinical trials.
Research on human embryonic stem cells is ethically controversial. Harvesting embryonic stem cells involves the destruction of human embryos, raising a moral concern. In addition, stringent regulations for obtaining Intellectual Property Rights (IPR) for products or materials used in research are major restraints for commercializing these services. Ethical approval should be obtained to store cell lines and tissues in biorepositories to avoid the usage of tissue for illegal purposes or to identify proxy diseases to claim insurance. Moreover, controversies surrounding the use of embryonic stem cells for research impede the market growth in several regions
You Can Purchase Complete[emailprotected]https://www.marketstatsville.com/buy-now/cell-therapy-market?opt=2950
The study categorizes the cell therapy market based on use type and therapy type at the regional and global levels.
The analysis of the cell therapy market is based on the use of stem cells for clinical and research purposes. The research-use segment dominated the market for the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem & non-stem cells) are majorly being used for research projects, which in turn, has led to a large revenue share of this segment in 2021. Cell-based therapies are all possibilities for the replacement, repair, restoration, and regeneration of damaged tissues, cells, and organs. As an alternative to traditional treatment strategies, researchers are investing heavily in developing effective and safe cell-based treatments.
Access full Report Description,TOC, Table of Figure, Chart, etc.@https://www.marketstatsville.com/table-of-content/cell-therapy-market
As per the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are some predominantly employed cell types for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, cornea cells, antigen-presenting cells, epithelial cells, and chondrocytes are some other cells that are being explored for the development of cell therapies.
Asia Pacificaccounts for the highestCAGR during the forecast period
Based on the regions, the global cell therapy market has been segmented across North America, AsiaPacific, Europe, South America, and the Middle East & Africa.In the Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.5% over the forecast period. Advancements in stem cell therapy in Asian countries are observed to be better than those in the U.S. This has resulted in Asia leading stem cell research. Several stem cell consortiums in Asian countries aim to ensure coordinated and focused R&D programs. Moreover, patients from western countries migrate to Asian countries for treatment, owing to the flexible legal framework.
Companies from Japan, South Korea, India, China, Taiwan, Singapore, and the rest of Asia were active participants in the conference. In addition, the large regional population and untapped potential present in the region have resulted in global firms entering the market. Moreover, this region offers relatively inexpensive manufacturing & operating units for conducting research. These factors are expected to play a major role in expanding the stem cell market in this region.
Request For Report Description @https://www.marketstatsville.com/cell-therapy-market
The cell therapy market is mildly concentrated in nature with few numbers of global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, and Celgene Corporation
Read the original here:
Cell Therapy Market Status and Size Report 2030 The Daily Vale - The Daily Vale
Personalized Cell Therapy Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities till 2028 |Novartis AG,…
personalized-cell-therapy-market
Global Personalized Cell Therapy Market is growing at a High CAGR during the forecast period 2022-2028. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market and This has brought along several changes in This report also covers the impact ofCOVID-19on the global market.
The latest research report, titled Personalized Cell TherapyMarket Added by Market Info Reports, provides the reader with a comprehensive overview of the Personalized Cell Therapy Industry and familiarizes them with the latest market trends, industry information, and market share. The report content includes technology, industry drivers, geographic trends, market statistics, market forecasts, producers, and raw material/equipment suppliers. Global Personalized Cell Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2028, with a CAGR of XX between 2022 and 2028.
Personalized Cell Therapy Market competition by top manufacturers as follow:Novartis AG, Vericel Corporation, Bellicum Pharmaceuticals, MolMed SpA, Cytori Therapeutics Inc, Gilead Sciences, Inc, Celgene Corporation, Bluebird Bio, Aurora Biopharma Inc, Saneron CCEL Therapeutics?Inc, Kuur Therapeutics, MediGene AG, Sangamo Therapeutics and More
Get Sample PDF including COVID19 Impact Analysis, full TOC, Tables and [emailprotected]https://www.marketinforeports.com/Market-Reports/Request-Sample/480529
Dont miss the trading opportunities on Personalized Cell Therapy Market. Talk to our analyst and gain key industry insights that will help your business grow as you create PDF sample reports.
The global Personalized Cell Therapy market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.
Market split by Type, can be divided into:By Cell TypeHematopoietic Stem CellSkeletal Muscle Stem Cell/Mesenchymal Stem Cells/LymphocytesBy TechniquePlatelet Transfusions/Bone Marrow Transplantation/Packed Red Cell Transfusions/Organ Transplantation
Market split by Application, can be divided into:Cardiovascular DiseasesNeurological DisordersInflammatory DiseasesDiabetesCancer
Share your budget and Get Exclusive Discount @https://www.marketinforeports.com/Market-Reports/Request_discount/480529
Market segment by Regions/Countries, this report covers:North AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa
Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2022Forecast Year: 2022-2028
Major factors covered in the report:
Detailed TOC of Personalized Cell Therapy Market Report 2022-2028:Chapter 1: Personalized Cell Therapy Market OverviewChapter 2: Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Market Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Personalized Cell Therapy Market ForecastContinued
Access full Report Description, TOC, Table of Figure, Chart, etc.@ https://www.marketinforeports.com/Market-Reports/480529/personalized-cell-therapy-market
The analysis objectives of the report are:
Does this report provide customization?Customization helps organizations gain insight into specific market segments and areas of interest. Therefore, Market Info Reports provides customized report information according to business needs for strategic calls.
Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/480529/personalized-cell-therapy-market
Why Choose Market Info Reports?:Market Info Reports Research delivers strategic market research reports, industry analysis, statistical surveys and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 600,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Chemical, Semiconductor, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.
Contact Us:Market Info Reports17224 S. Figueroa Street,Gardena, California (CA) 90248, United StatesCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Website: http://www.marketinforeports.com
AMERICAN CRYOSTEM CORP MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS (form 10-Q) – Marketscreener.com
Forward-looking Statements
Inadequate capital and barriers to raising the additional capital or to
Litigation with or legal claims and allegations by outside parties; and
Insufficient revenues to cover operating costs.
The Company is expanding its efforts to attract and cultivate collaborativepartners to accelerate its product development efforts, harnessing itsmanufacturing platform and tissue processing platforms. The R&D collaborationsare to discover, develop, and commercialize cellular therapies, laboratoryproducts and combinations thereof with synergistic technologies to createregenerative medicine applications and develop new intellectual property.
1. The Company filed its first Investigational New Drug Application (IND) with
the US Food and Drug Administration (FDA) for the ATCELL cellular therapy
product. The IND filing is titled "ATCell Expanded Autologous Adipose Derived
Mesenchymal Stem Cells deployed via Intravenous Infusion for the Treatment of
Post-Concussion Syndrome (PCS) in Retired Athletes and Military Personnel",
File number 19089, which was approved by the FDA on September 17, 2020. The
Company intends to invite additional developers of cellular therapies to
initiate additional arms of the clinical study focused on the use of ATCELL
for use in systemic inflammatory response relief for patient suffering from
systemic diseases. A number of these additional study targets have been
identified and ongoing discussions support the Company's belief that clinical
investigations can be developed and rapidly added upon completion of the new
2. DMD - The Company has completed the protocol for the treatment of Duchene
Muscular Dystrophy and is in final discussions with its Collaborative partner,
to select the principal investigator (PI) and clinical trial site selection.
3. Long COVID - The Company has completed the protocol for treatment of Long
COVID and is currently finalizing its FDA filings. We have completed, along
with a government partner the clinical protocol for a new Investigational New
Drug (IND) application to be filed with FDA within the next 90 days for Long
COVID. According to the Centers for Disease Control and Prevention,
"post-COVID conditions can be considered a lack of return to a usual state of
health following acute COVID-19 illness." In the US, following COVID recovery,
it is reported that up to 30% of those afflicted, diagnosed, or treated for
COVID-19 have continuing symptoms and medical complications following recovery
4. Wound Healing - the creation of topical applications and ingredients used by
physicians in the wound care and cosmetic industries as well as therapeutic
cellular applications and bio-materials development. An initial pilot study
involving a minimum of 10 participants for the assessment of its autologous
tissue products for the wound healing market is underway. The Company is
combining its tissue products, which do not require FDA approval, with current
standard-of-care methods to accelerate and improve the healing of diabetic and
5. ATGRAFT - products include adipose tissue and cell sample processing and
storage as a form of personal "bio-insurance", and adipose tissue (fat)
storage for cosmetic fat engraftment procedures. High demand for pure and
natural aesthetics in fast growing cosmetic industry with non-FDA required
Tissue Processing and Storage Services:
Laboratory Products; Culture Medium, and Manufacturing Services
The Company has created several versions of its ACSelerate cell culture mediaincluding:
ACSelerate-MAX - xeno serum free cell culture media,
ACSelerate-SFM - animal serum free cell culture media,
ACSelerate-LSM - low FBS (0.05%) cell culture media,
ACSelerate-CY- for differentiation of ATCELLinto chondrocytes (ATCELL-CY),
ACSelerate-OB- for differentiation of ATCELLinto osteoblasts (ATCELL-OB)
ACSelerate-AD - for differentiation of ATCELLinto adipocytes (ATCELL-AD)
ACSelerate-MY- for differentiation of ATCELL into myocytes (ATCELL-MY)
ACSelerate-CP- non-DMSO (Dimethyl Sulfoxide) cellular cryopreservation media
ACSelerate-TR- sterile transportation medium designed to maintain the
viability of the tissue during the shipment of adipose tissue to our processing
International Licensing Program - COVID RISK FACTOR
(https://www.transparencymarketresearch.com/pressrelease/stem-cells-market.htm)
China
Thailand
Japan
Collaborations / Partnering Opportunities / Acquisitions
WRNMMC
WRNMMC is part of The Military Health System (MHS) which is the enterprisewithin the United States Department of Defense that provides health care toactive duty, Reserve component and retired U.S. Military personnel and theirdependents.
To ensure that all active and reserve medical personnel in uniform are trained
and ready to provide medical care in support of operational forces around the
world.
To provide a medical benefit commensurate with the service and sacrifice of
more than 9.5 million active-duty personnel, military retirees, and their
families.
The MHS also provides health care, through the TRICARE health plan, to:
Active-duty service members and their families,
Retired service members and their families,
Reserve component members and their families,
Surviving family members,
Medal of Honor recipients and their families
Some former spouses, and
Others identified as eligible in the Defense Enrollment Eligibility Reporting
Intellectual Property
Systems and Methods for the Adipose Tissue Digestion U.S. Serial No.Digestion of Adipose Tissue Laboratory Processing 13/646,647 filed OctoberSamples Obtained From a Client Methods
Additionally, the Company has in-licensed the following IP:
Wound healing compositions and Protein Genomics andmethods using tropoelastin and American CryoStem USPTO: #6,808,707lysyl oxidase
Market Size and Opportunities
Regenerative Medicine Market
Development of Regional U.S. Markets
Physician Network
Development of International Markets
Corporate Information
Available Information
Results of Operations - Three Months
The Company's revenue for the quarter ended March 31, 2022, increased to $31,935versus $1,935 in the same period of Fiscal 2021.
Liquidity and Capital Resources
Accounts Receivable decreased to $65,680 at March 31, 2022 from $78,782 atSeptember 30, 2021.
There was no significant impact on the Company's operations as a result ofinflation for the six months ended March 31, 2022.
The Company leases Equipment at its laboratory from NFS Leasing, Inc. Leasepayments are $2,993.62 per month for eighteen (18) months. The final leasepayment is scheduled for January 1, 2023. When the final payment is made, theCompany will own the equipment. See Note 11 . Leases in the FinancialStatements.
The Company was not party to any litigation against it and is not aware of anylitigation contemplated against it as of March 31, 2022. See also LegalProceedings below.
From time to time the Company takes advances makes principal payments on thenote. During the six months ended March 31, 2022, the Company was advanced$1,729 and made payments of $18,000 on the note.
The principal balance of the Note is $131,505 at March 31, 2022 and 147,775 atSeptember 30, 2021.
Terms of the Series A Voting Convertible Preferred Shares are as follows:
1. Each Series A Share is convertible into 20 shares of American CryoStem common
stock $0.001 par value, subject to any recapitalization event.
2. Stated annual dividend of $0.20 per share payable quarterly in cash or stock
at the discretion of the Company's Board of directors.
The rest is here:
AMERICAN CRYOSTEM CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS (form 10-Q) - Marketscreener.com
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare – Valdosta Daily…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 24, 2022--
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2022. Genentech and its partners will present clinical studies across medicines, comprehensive genomic tests, and real-world data at this years meeting.
At ASCO this year, progress from our portfolio, partnerships and collaborations showcase our commitment to advance innovation in cancer care, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. Were especially pleased to present data from our broad hematology portfolio, including pivotal data for glofitamab, a potential first-in-class bispecific antibody that may improve the lives of people with heavily pre-treated aggressive lymphoma.
Focusing on improving outcomes in non-Hodgkin lymphoma
New and updated data in non-Hodgkin lymphoma will be presented at ASCO. This includes pivotal data from the Phase II NP30179 study investigating glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma, where as many as 40% of patients will relapse, at which point treatment options are limited and survival is shortened. Glofitamab is part of Genentechs broad bispecific antibody development program, which may offer a new immunotherapy-based approach to tackle a range of blood cancers. It is being investigated in several clinical trials including the STARGLO Phase III study, evaluating glofitamab in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera/Rituxan (rituximab) in combination with GemOx in autologous stem-cell transplant ineligible relapsed or refractory DLBCL. In addition, key findings from an analysis of the Asia subpopulation from the pivotal Phase III POLARIX study investigating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan plus cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with newly diagnosed DLBCL will be featured. Polivy plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated DLBCL in more than 20 years, potentially transforming treatment for people with this disease.
Driving innovation in personalized cancer care
More than 20 new pieces of research from partnerships with Foundation Medicine will be presented, which continue to support innovation as well as progress in personalized cancer care. This includes new data from the Phase II Profiler02 study,* which investigates the use of a comprehensive genomic profiling testing panel from Foundation Medicine, with the aim of informing possible treatment decisions for patients based on their tumors unique genomic information.
Data from the imCORE network
Additionally, three abstracts from the Immunotherapy Centers Of Research Excellence (imCORE) Network will be presented at ASCO: a Phase I study** investigating autogene cevumeran (an mRNA-based individualized neoantigen-specific immunotherapy [iNeST]***) in the adjuvant setting of pancreatic ductal adenocarcinoma; a data mining study** evaluating intermediate endpoints for survival in metastatic breast cancer in the real-world setting; and a study identifying mechanisms of acquired resistance to immune checkpoint blockade.**
imCORE is an academic-industry network for scientific collaboration. Established by Genentech and connecting experts from 26 leading institutions around the globe, imCORE is committed to advancing and accelerating cancer immunotherapy research. imCORE is an example of Genentechs dedication to collaborating with the global cancer community to further understand cancer biology and immunology, help inform the development of potential future treatment, and transform patients lives.
Genentechs data presented at ASCO will feature its efforts to drive innovation and commitment to health equity through delivery of pioneering medicines and personalized cancer care that together improve outcomes for every patient while reducing the cost to society, inclusive clinical trials that remove barriers to participation, partnerships that multiply our ability to address challenges in cancer care, and bringing innovation into earlier stages of disease to maximize a chance of cure.
Overview of key presentations featuring Genentech medicines
Medicine
Abstract title
Abstract number
Blood cancer
Glofitamab
Glofitamab in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and 2 prior therapies: Pivotal Phase II expansion results
#7500
Mosunetuzumab
CELESTIMO: a Phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received 1 line of systemic therapy
#TPS7588
Polivy
Asia subpopulation analysis from the Phase III POLARIX trial
#7558
Initial safety run-in results of the Phase III POLARGO trial: polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
#7551
Lung cancer
Tiragolumab
SKYSCRAPER-02: primary results of a Phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) plus carboplatin plus etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)
#LBA8507
Breast cancer
Giredestrant
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2 eBC): final analysis of the randomized, open-label, international Phase 2 coopERA BC study
#589
Inavolisib
Long-term safety of inavolisib (GDC-0077) in an ongoing Phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib (palbo) and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2) metastatic breast cancer (BC)
#1052
Tumor agnostic treatment and personalized healthcare
Rozlytrek
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)
#LBA9023
Rozlytrek
Trial in progress: a randomized Phase 3 study of entrectinib vs crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)
#TPS9141
Comprehensive genomic profiling
(IIS, Centre Lon Brard)
Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized Phase II trial*
#3130
Comprehensive genomic profiling
Clinical and genomic characteristics of patients with durable benefit from immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC)
#9048
Comprehensive genomic profiling
ctDNA Shed as a Tool to Select Immune Checkpoint Inhibitors (ICPI) with or without Chemotherapy for Patients (pts) with advanced Non-small Cell Lung Cancer (aNSCLC)
#9045
Comprehensive genomic profiling
Trial in progress: LCMC LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
#TPS8596
Real world data
A real world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD)
#8525
Real world data
Real world analysis of quantitative MET copy number (CN) as a biomarker in advanced NSCLC (aNSCLC)
#9123
Real world data
Ancestry-based differences in gene alterations in non-small cell lung cancer: real-world data using genetic ancestry analysis
#9125
imCORE,
ISR, Genentech
Identifying mechanisms of acquired immune escape from sequential, paired biopsies**
#2519
imCORE
ISR, Dana-Farber Cancer Institute
Real-World Progression-Free Survival (rwPFS) and Time to Next Line of Therapy (TTNT) as Intermediate Endpoints for Survival in Metastatic Breast Cancer: A Real World Experience**
#6520
imCORE
ISR, Memorial Sloan Kettering Cancer Center
Phase I Trial of Adjuvant Autogene Cevumeran, an Individualized mRNA Neoantigen Vaccine, for Pancreatic Ductal Adenocarcinoma**
#2516
* IIS, investigator-initiated study
** ISR, institution-sponsored research
*** jointly developed by Genentech and BioNTech
About Polivy (polatuzumab vedotin-piiq)
Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkins lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Seagen ADC technology and is currently being investigated for the treatment of several types of NHL.
Polivy U.S. Indication
Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies.
The accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy.
Important Safety Information
Possible serious side effects
Everyone reacts differently to Polivy therapy, so its important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. A patients doctor may stop or adjust a patients treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects.
Nerve problems in arms and legs: This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patients doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns
Side effects seen most often
The most common side effects during treatment were:
Polivy may not be for everyone. A patient should talk to their doctor if they are:
These may not be all the side effects. Patients should talk to their healthcare provider for more information about the benefits and risks of Polivy treatment.
Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.
Please visit http://www.Polivy.com for the full Prescribing Information for additional Important Safety Information.
About Tecentriq (atezolizumab)
The rest is here:
Data at the 2022 ASCO Annual Meeting Highlight Genentech's Continued Commitment to Innovation in Oncology and Personalized Healthcare - Valdosta Daily...
Beware of unproven stem cell therapies – The Jackson Sun
RANDY HUTCHINSON| Better Business Bureau
The FDA says that stem cell products may offer the potential to treat many medical conditions and diseases for which few alternative treatments exist, but almost all of them have yet to be proven to be effective or safe. That hasnt stopped unscrupulous medical professionals and other promoters from touting them as miracle cures.
Stem cells are sometimes called the bodys master cells because they develop into blood, brain, bones and the bodys other organs. Stem cells that come from bone marrow or blood are routinely used to treat cancer and other disorders of the blood and immune system. But other uses, including treating COVID-19, have not been properly studied under an FDA Investigational New Drug Application, which includes providing sufficient data from human clinical testing to help evaluate a products potential risks.
The FDA cites these potential safety concerns for unproven treatments:
There are safety risks even with your own stem cells and contamination can occur if cells are manipulated after removal.
The FTC and Georgia Attorney General sued the co-founders of the Stem Cell Institute of America for allegedly targeting seniors with bogus claims that its therapy could treat arthritis, joint pain and other orthopedic ailments. The agencies said the company also claimed its stem cell therapy is comparable or superior to surgery, steroid injections and painkillers. A related company trained chiropractors and other healthcare practitioners in making similar claims. They also hosted free educational seminars for consumers at which they promoted injections that cost approximately $5,000 per joint, with many patients receiving multiple injections.
This wasnt the FTCs first enforcement action against deceptive stem cell therapy claims. In 2018, a California physician and his companies settled with the FTC over claims their amniotic stem cell therapy could treat Parkinsons disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, heart attacks and a host of other serious ailments. The defendants earned at least $3.3 million offering injections that cost up to $15,000.
The only stem cell products approved by the FDA for use in the United States consist of blood-forming stem cells derived from umbilical cord blood. Theyre approved for limited use in patients with disorders that affect the production of blood.
In bringing the most recent action, the Acting Director of the FTCs Bureau of Consumer Protection said, At best, the use of unproven products or therapies can cost consumers thousands of dollars without affording them any results. At worst, it can be harmful to their health.
If youre considering a stem cell treatment, the FDA says to make sure its FDA-approved or being studied under an Investigational New Drug Application. The FTC and BBB offer these additional tips:
Randy Hutchinson is the president of the Better Business Bureau of the Mid-South. Reach the BBB at 800-222-8754.
See the original post:
Beware of unproven stem cell therapies - The Jackson Sun
Stem Cell Therapy Market Size, Business Opportunities and Forecast to 2029 The Oxford Spokesman – The Oxford Spokesman
New Jersey, United States,-ThisStem Cell TherapyMarketreport provides a clear picture of key players growth as well as the qualitative aspects of business in each area. ThisStem Cell TherapyMarket Report provides a current report on revenue generation, recent trends, financial status, and costing, as well as business profiles and financial status. The competitive landscape and potential growth factors are presented in thisStem Cell TherapyMarket Report.This way market report buyers can get a clear picture of the significant growth and the resulting market strategy. Granular market data would help monitor potential profitability and make critical growth decisions.
Significant industry central participants are included in thisStem Cell Therapymarket report. Diverse market factors like sort, size, applications, and end-clients have been incorporated to examine organizations altogether in thisStem Cell Therapymarket report. Significant mainstays of the organizations, companies and industries that influence the high points and low points of organizations are moreover recollected for thisStem Cell Therapymarket report.The research, interviews with key market players, and questionnaire have been compiled based on the continuous changes in the market, challenges and restraints faced by organizations, and global autonomies to expand the field in the coming years.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=24113
This unique Stem Cell Therapy market report also discusses COVID-19 impact and influence on the worldwide market. How might one work around it or come up with fresh techniques so that COVID-19 doesnt stifle market growth are also discussed this report. This fascinating Stem Cell Therapy market report has proven to be of great benefit to current market participants by providing them with a broad understanding of market dynamics. This Stem Cell Therapy market report is a reliable technique of the general industry scenario that indicates basic leadership if they will gain or lose money in this market.
Key Players Mentioned in the Stem Cell Therapy Market Research Report:
Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co. Ltd., Nuvasive RTI Surgical Allosource
Stem Cell TherapyMarket Segmentation:
Stem Cell Therapy Market, By Cell Source
Adipose Tissue-Derived Mesenchymal Stem CellsBone Marrow-Derived Mesenchymal Stem CellsCord Blood/Embryonic Stem CellsOther Cell Sources
Stem Cell Therapy Market, By Therapeutic Application
Musculoskeletal DisordersWounds and InjuriesCardiovascular DiseasesSurgeriesGastrointestinal DiseasesOther Applications
Stem Cell Therapy Market, By Type
Allogeneic Stem Cell Therapy Market, By ApplicationAutologous Stem Cell Therapy Market, By Application
Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113
Stem Cell Therapy Market Report Scope
Determining the pulse of the market becomes easy through this in-detail Stem Cell Therapy market analysis. Key players can find all competitive data and market size of major regions like North America, Europe, Latin America, Asia-Pacific and Middle East. As part of the competitive analysis, certain strategies are profiled which are pursued by key players such as mergers, collaborations, acquisitions and new product launches. These strategies will greatly help industry players to strengthen their market position and grow their business.
Key questions answered in the report:
1. Which are the five top players of the Stem Cell Therapy market?
2. How will the Stem Cell Therapy market change in the next five years?
3. Which product and application will take a lions share of the Stem Cell Therapy market?
4. What are the drivers and restraints of the Stem Cell Therapy market?
5. Which regional market will show the highest growth?
6. What will be the CAGR and size of the Stem Cell Therapy market throughout the forecast period?
For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-therapy-market/
Visualize Stem Cell Therapy Market using Verified Market Intelligence:-
Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.
VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.
Visualize Stem Cell Therapy Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/
About Us: Verified Market Research
Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.
Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.
We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.
Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.
Contact us:
Mr. Edwyne Fernandes
Verified Market Research
US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Website:- https://www.verifiedmarketresearch.com/
See the original post here:
Stem Cell Therapy Market Size, Business Opportunities and Forecast to 2029 The Oxford Spokesman - The Oxford Spokesman
Penn Highlands Healthcare surgeon pioneers innovative ACL surgery offering faster recovery – The Courier-Express
DuBOIS Cayleigh Walkers hopes for a successful basketball season were almost benched when she tore her ACL playing summer league basketball at the YMCA in July 2021. However, the Clearfield High School sophomore resumed training just three weeks following her August surgery, fast tracking her return to the court with the Lady Bison varsity basketball team.
I was going up the court and felt it pop, Cayleigh recalled. I was in so much pain. I had to sit out the rest of the game while some of the parents tried to stretch it out. I was eager to have it examined because we were leaving for the beach two days later. Fortunately I was able to get an appointment to have it examined the next morning.
Cayleigh and her parents chose Penn Highlands Orthopedics and Sports Medicine for her care. At Penn Highlands, she was examined by Tyler Beers, PA-C, who tested her range of motion and felt around the injured area. He gave her a brace to wear and ordered an MRI which was scheduled the following week when the Walkers returned from their vacation.
The MRI revealed the torn ACL. The next day, Cayleigh met with Dr. Matthew A. Varacallo, medical director of Orthopedic Robotic Surgery at Penn Highlands Healthcare. The orthopedic surgeon specializes in sports medicine, total joint reconstruction, accelerated rehabilitation protocols and functional return to sports after surgeries and procedures.
Named to the Top 65 Total Knee Replacement Surgeons to Know by Beckers ACS Review, Dr. Varacallo pioneered the innovative Fertilized ACL technique along with Dr. Chad Lavender, an orthopedic surgeon at Marshall University in West Virginia. Currently, they are the only two surgeons in the US using the technique when performing ACL reconstruction surgery.
Typically, when an ACL tear occurs, one third of the athletes re-tear the same side or injure the other knee; but, the theory behind the Fertilized ACL technique is to improve and expedite bone tunnel healing rates, followed by graft revascularization and ligamentization (the process by which the tendon becomes a ligament) to improve graft function and incorporation into the knee joint, explained Dr. Varacallo.
The Fertilized ACL procedure begins when bone marrow is removed from the tibia the long bone on the inside of the lower leg which is rich in growth hormone and stem cells. A specialized perfusionist takes 60 milliliters of the bone marrow and spins it down to bone marrow aspiration concentrate (BMAC) which is used to initiate healing. The BMAC is mixed with bone graft. Small tunnels are then made in the femur and tibia to place the graft during the procedure. The bone graft mixture and stem cells/growth factors are then injected into the tunnels to help stimulate them to heal faster. Once the tunnels heal, the tendon can in theory possibly transform into a ligament faster.
This is truly a cutting edge procedure, explained Dr. Varacallo. In traditional ACL surgeries, the pressurized tunnels can be risk factors for re-injury because they can take up to six or seven months to heal. However, with the Fertilized ACL procedure, the tunnels heal faster because the graft starts to incorporate into the body faster. In fact, four weeks post surgery, you cannot even see the bone tunnels, the surgeon added.
Dr. Varacallo considers Cayleigh the poster child for successful ACL reconstruction because she is achieving milestones sooner than expected, and Samantha (Sam) Morgan, MS ATC PES, a certified athletic trainer with Penn Highlands Healthcare as well as with the Clearfield Area School District agrees.
Three days following surgery, Cayleigh began rehab, and at three and one half weeks post op she was running, and six to seven weeks following surgery she was punting a soccer ball. In contrast, with traditional ACL surgery, we would not see that type of progress until three or four months post op, Ms. Morgan detailed.
According to Dr. Varacallo, Cayleigh is several months ahead of where she should be in terms of her progress based on the functional testing ACL Report Card, The Report Card, which is used to measure how well a patient is meeting 15 different functional test milestones at two, four, six and eight months post op, was developed at the University of Kentucky where Dr. Varacallo completed his fellowship in Orthopedic Surgery and Sports Medicine.
The ACL Report Card is a great benchmark tool because it not only shows the medical team the patients progress, it gives the athlete something to shoot for in their rehab, said Dr. Varacallo.
I had four months of rehab five days a week, Cayleigh said, The first few weeks were challenging because I was in some pain, but Sam pushed me and helped me get through it.
At two months after surgery, Cayleigh was testing stronger on the surgery side than on the other non-injured side. One of the factors that contributed to her faster recovery was that prior to surgery she and the other patients who have Fertilized ACL reconstruction surgery have prehab.
We cannot operate on a stiff and weak knee, so prior to surgery, we have the patient undergo motion and strengthening exercises to improve outcomes following surgery, Dr. Varacallo explained. The stronger the knee heading into surgery, the faster the recovery.
In addition to enhancing flexibility, prehab teaches patients the exercises they will be doing during post-surgery rehab so that they are already familiar with what their physical therapy will entail.
Cayleigh had aggressive prehab, said Morgan. In addition to promoting flexibility of the knee, it is an educational tool that helps the patient understand the how and why of the injury and healing. Three days following surgery, Cayleigh started rehab, and because she had the prehab, she already knew how to perform her exercises.
The prehab, surgery and rehab are all interdependent on each other. In fact, Dr. Varacallo uses an analogy to tie the process together. I think of the reconstruction and healing process as a house the prehab is the foundation, surgery is the main living level and rehab is the attic.
According to Cayleighs mother, Tammy Walker, her daughters fast recovery is a combination of three factors, Dr. Varacallos innovative Fertilized ACL technique, the aggressive rehabilitation and equally important the determination by Cayleigh and Morgan to get her back to where she could play again.
We are very impressed with Dr. Varacallo, said Walker. He was very thorough and went through everything with us and even called to check on her progress following the surgery.
Ashley Cain supports parents of girl, 5, battling same cancer which killed his baby – The Mirror
Exclusive:
Football ace Ashley Cain and his girlfriend Safiyya Vorajee have been supporting parents of children battling cancer. The couple's baby girl Azaylia died last April
Image: Instagram)
Footballer Ashley Cain has been offering hope and solace to parents of a little girl battling the cancer that claimed the life of his own precious daughter.
Reality star Ashley and girlfriend Safiyya Vorajee have been supporting dozens of sick childrens families since the death of their baby girl.
Beloved Azaylia died last April after a courageous fight against the blood cancer acute myeloid leukaemia.
The ex-Coventry City winger and his partner have now struck up a special friendship with the family of five-year-old Esha Nadeswaran, who has spent eight months fighting the same disease at Londons Great Ormond Street Hospital.
Her dad Rishya, 45, of Gants Hill, North East London, said: Esha is our absolute hero and she is incredible. With our journey, it is like a marathon with no finish. We dont know when it is going to end and so we cant even pace ourselves.
There have been days where Ive gone to bed, crawled up and cried alone. But no matter how bad a day you are having and how much you hurt inside, Ashley reminded me you must stay positive and happy for your child.
He told me not to think too far ahead and do whatever I needed to do to support Esha. Its horrible to be told your child has cancer.
Listening to Ashley, and how vulnerable he felt, really struck a chord. Our chat has kept me going.
Former Ex On The Beach star Ashley, 31, and Safiyya, 34, were devastated to lose Azaylia when she was just eight months old.
She had been given stem cell treatment, which involves replacing damaged cells with healthy ones from a blood-match donor.
Ashley said Azaylia had the heart of a lion and he was given precious extra months with her after 100,000 people registered to be a donor.
The couple got involved in Eshas battle after Rishya and wife Kavitha, 41, appealed to members of the South Asian community to volunteer to be stem cell donors.
Esha has been in hospital since last May. She has had gruelling chemo and, in October, an emergency stem cell transplant. With her parents at her bedside, constant care includes regular platelet and red blood cell transfusions.
Rishya recalls the day they received the diagnosis. He says: She had been having tummy issues. Doctors ran tests and we were told wed receive the results in a fortnight. Two hours after returning home, they rang and we knew something was badly wrong. We rushed back and were told she had an acute form of leukaemia. It has been utterly heartbreaking.
Eshas Sri Lankan heritage meant it was hard to find a donor match and the family launched a social media campaign. Safiyya then reached out.
Rishya says: I arranged a Zoom chat with Safiyya and Ashley and I spoke father to father about what it feels like to be told your child has cancer. It was very emotional.
Ashley and Safiyya also recorded a video message on Eshas birthday.
Rishya, who works in banking, says: Esha really liked it. She is such a caring little girl and the way she has bounced back to defy doctors is something of a miracle.
She is always the one who goes from room to room cheering up the other children.
Rishya and his family now have 10,000 Instagram followers. But what they havent shared is their sacrifices to give her the best possible chance of survival.
Forming a Covid bubble, Rishya and his wife have had to live apart from elder daughter Ria, 10, who is with her grandparents.
They see her once a week at arms length and were apart at Christmas and on both girls birthdays. Its been really tough, says Rishya. My wife and I take it in turns to stay with Esha. The Young Lives vs Cancer charity has kindly been able to offer accommodation for the other to stay nearby.
We have been locked in this bubble for months now and its exhausting.
Ashley and Safiyya have helped dozens of parents. They set up a foundation raising money for treatment that may not be available on the NHS.
Image:
He says: No matter how painful it is, our mission is to really help and battle for these kids fighting cancer.
We speak to parents privately and try to guide them through the experience. We know first hand the stress and trauma parents have to go through.
Eshas dad and I talked about appreciating every single moment, making sure your child thinks theres nothing wrong. You need to stay positive and be the best you can be.
The pain of losing Azaylia is with us every minute. We go to her resting place every day and I want to hold this pain forever to use it effectively to help other children have a better chance.
Safiyya adds: So many children are suffering and we want to help.
The couple are planning a fundraising cycling event in June in conjunction with the Tour of Cambridgeshire.
Ashley says: Wed like everyone to wear orange and create a sea of orange so that Azalyia can look down from heaven and see what an amazing effect she has had on this world.
To join the cycle event, go to cycleforazaylia.com. Get updates on Esha at instagram.com/for_esha
Esha has the illness that cost Azaylia her life acute myeloid leukaemia, cancer of the white blood cells.
It starts in the bone marrow and spreads to the bloodstream and is very rare in young children.
The risk increases with age and it is most common in people aged over 75.
Acute leukaemia means it progresses quickly and chemotherapy is the main treatment, killing off as many unhealthy cells as possible and reducing the risk of the patient suffering a relapse.
Stem cell therapy involves removing a persons unhealthy cells and replacing them with healthy ones from a donor.
The new cells travel in the blood of the patient to the bone marrow, where they attach and grow.
Read More
Read More
Continue reading here:
Ashley Cain supports parents of girl, 5, battling same cancer which killed his baby - The Mirror
Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report – DocWire News
This article was originally published here
J Oncol Pharm Pract. 2022 Jan 27:10781552221074269. doi: 10.1177/10781552221074269. Online ahead of print.
ABSTRACT
INTRODUCTION: Plasma cell leukemia (PCL) is a rare but aggressive variant of multiple myeloma (MM) with a poor prognosis. Due to the limited number of prospective clinical trials studying PCL, treatment options are often extrapolated from data available for the treatment of MM. Venetoclax has recently demonstrated antimyeloma activity in patients with relapsed/refractory MM carrying the t(11;14) translocation. However, few cases have reported the analogous efficacy of venetoclax in PCL.
CASE REPORT: A 64-year-old Caucasian male developed relapsed PCL despite treatment with hyperCD (hyperfractionated cyclophosphamide and dexamethasone) and Dara-KRd (daratumumab, carfilzomib, lenalidomide, dexamethasone). Due to the refractory nature of his disease and the presence of a t(11:14) translocation, the patient was subsequently initiated on venetoclax 400 mg daily and dexamethasone 4 mg once weekly.
MANAGEMENT AND OUTCOME: The patient achieved a complete response by International Myeloma Working Group criteria three months after initiating venetoclax-dexamethasone, including a repeat bone marrow biopsy that showed no abnormal plasma cells. He successfully underwent consolidation with melphalan-based autologous stem cell transplantation. He remains disease-free 9 months after venetoclax initiation.
DISCUSSION: Combination all-oral therapy with venetoclax and dexamethasone can induce deep hematologic responses in patients with relapsed/refractory PCL carrying the t(11;14) translocation.
PMID:35084252 | DOI:10.1177/10781552221074269
Original post:
Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report - DocWire News
Hiltzik: The battle against unlicensed stem cell clinics – Los Angeles Times
In 2017, the Food and Drug Administration closed a loophole exploited by clinics pitching unproven, ineffective and potentially hazardous stem cell therapies directly to consumers.
Those treatments were illegal, the FDA ruled. That was the good news. The agency, however, suspended its enforcement for three years to give these operators time to get right with its regulations. During the pandemic, the FDA added six months to the deadline, so its period of regulatory forbearance expired on May 31.
What happened in the meantime? Instead of stem cell purveyors reaching out to the FDA to work out how to meet federal regulations, a torrent of shady operations poured into the field so many that the task of protecting the public from them may now exceed the FDAs capabilities.
Dont believe the hype.
The FDAs warnings against unlicensed stem cell clinics
Thats the concern of Leigh Turner, a public health expert at UC Irvine, longtime critic of stem cell treatment claims and author of a new study that tracked the explosion of businesses offering purported stem cell treatments and cures during the FDAs hands-off period.
The paper is essentially a follow-up to a seminal study Turner conducted with Paul Knoepfler of UC Davis in 2016, which identified 351 businesses hawking stem cell treatments directly to consumers through 540 clinics.
Newsletter
Get the latest from Michael Hiltzik
Commentary on economics and more from a Pulitzer Prize winner.
Enter email address
Sign Me Up
You may occasionally receive promotional content from the Los Angeles Times.
Turners new study, which was published Thursday in the peer-reviewed journal Cell Stem Cell, identified 1,480 businesses operating 2,754 clinics nationwide.
That hardly seems like progress, Turner told me. Now the problem the FDA faces is four times larger than what existed in 2016. The FDA only has so many employees and so many inspectors. They dont really have enough inspectors to send them to 1,480 businesses.
The FDA hasnt been entirely inactive. Over the last 3 years it issued more than 400 warning letters to stem cell marketers, clinics and healthcare providers, notifying them that they may be operating outside the law. But it hasnt done much more than that.
The proliferation of stem cell claims points to a major breakdown in Americas healthcare regulatory system generally.
Given the size of this clinic industry the risk to the public is huge, Knoepfler says. The industry threatens the authority of the FDA itself. It might be one of the largest and most serious noncompliance challenges that the FDA has ever faced in its history. What would the FDA do if pharmaceutical firms were selling unapproved drugs at 2,700 clinics all over the country? It would be considered a national emergency.
State medical boards, which have at least nominal authority to ride herd on the practices of licensed physicians in this field, have done little of note. The Medical Board of California, a state that with 347 clinics is the largest center of facilities in Turners database, created a two-member Stem Cell and Regenerative Therapy Task Force in 2018.
The task force hasnt met since 2019, according to a board spokesman, and hasnt issued any reports. Board records indicate that it received 33 complaints about stem cell treatments from 2018 through this year, and has taken no disciplinary or administrative actions in response.
California hasnt done much to rise to the challenge, Turner says.
A few words may be useful about the regulatory environment. The chief targets of the FDAs enforcement program, such as it is, have been clinics that extract fat cells from customers through liposuction and then supposedly extract stem cells from the fat and inject them back into the customers bodies as treatments. Some purportedly extract stem cells from customers bone marrow.
The conditions for which these treatments are commonly offered include pain, sports injuries, heart and lung disease, multiple sclerosis, Parkinsons, Alzheimers, autism, diabetes, vision loss and erectile dysfunction.
No scientifically validated evidence exists for any of these claims, the FDA notes. The only stem cell products approved by the FDA are a few derived from umbilical cord blood, and then only for a very limited category of blood system diseases.
Beyond that, the agency advises consumers, Dont believe the hype.
The purveyors of unproven and unlicensed treatments identified by Turner charge as much as $28,000 for their services, with an average of more than $5,000 often ponied up by unwary customers seduced by advertising and irresponsibly credulous reports in the press.
The treatments typically are not covered by insurance, so customers are paying out of pocket.
Under FDA regulations, most stem cell treatments being sold to customers are illegal. Thats because the products are deemed to be unlicensed drugs. Exceptions exist for some surgical procedures and in cases in which almost identical cells are reinjected into patients, but the FDA says few of the targeted clinics qualify.
The FDAs position was endorsed by a federal judge in Miami in 2019, when she shut down a clinic that the FDA had sued for offering unapproved stem cell procedures. The clinic lost an appeal of her ruling in June. A separate lawsuit the FDA filed against California Stem Cell Treatment Center and associated businesses is awaiting a verdict from U.S. Judge Jesus G. Bernal in Riverside following a trial he conducted in May.
The offered treatments are not only unproven, but potentially hazardous. Reports of adverse outcomes from unlicensed treatments have proliferated, some of them gruesome. In a report issued in June, researchers at the Pew Charitable Trusts documented reports of adverse outcomes from 360 patients between 2004 and mid-2020.
These figures are almost certainly conservative, as clinics operating outside the law are highly unlikely to follow rules mandating that they report adverse reactions among their customers. Indeed, the FDA in its lawsuit against the California defendants asserted that numerous adverse outcomes experienced by their patients were not reported to the agency.
A note cited by the FDA from the file of one patient who was unable to walk for six months after receiving a stem cell injection in her knee from a clinic associated with the defendants, read, Not all treatments are successful. Not really adverse event due to the treatment. At trial, defendant Mark Berman said the clinics product has had very rare adverse events.
FDA officials have said that their expectations that stem cell treatment purveyors would engage with the agency during the forbearance period to work out how to come into compliance with its regulations proved wildly optimistic. We have been very disappointed in the number of clinics that have come in, Wilson Bryan, a top FDA official, told a law conference in June.
The FDA may not have recognized that the clinics they were targeting never had any intention of meeting its regulations.
Were talking about a huge number of businesses that are failing to comply with federal law, but have no reasonable prospects of coming into compliance, Turner says. They dont have clinical research programs. They dont have qualified stem cell researchers. Theyre just peddlers putting out a shingle on the internet.
Instead of using that three-year period to change their practices and comply with the law, lots of businesses stayed in the marketplace and did nothing to change what they were doing, and a huge number of other operators poured into the marketplace.
Over the last five years or so, or since Turner and Knoepfler published their original report, stem cell treatment claims have become just one more offering by practitioners advertising other services of dubious effectiveness.
Stem cell treatment has become just a routine claim, Turner says, from all kinds of orthopedic clinics, sports medicine clinics, podiatrists, chiropractors, naturopaths, wellness clinics. They market an array of services and stem cells are just something else they can sell, like cryotherapy or acupuncture.
Its unclear whether some of these operations really even use stem cells some may be offering just costly placebos, Turner conjectures.
The threat to public health from unlicensed and unproven stem cell claims will only get worse if the FDA fails to act forcefully.
People make the mistake of thinking that these are businesses that will go under if they get a bit of a push from the FDA or FTC [Federal Trade Commission] Turner says. The truth is that some of them are quite well capitalized and have the resources to go out and join these battles.
The FDA may be waiting for Judge Bernals ruling before taking the next step but thats dependent on his finding in the FDAs favor. It could seek mass injunctions, admittedly a big practical challenge, Knoepfler says. He adds, Looking ahead, the agency should take quick, large-scale, and even creative actions if it has any hope to make a dent in this clinic industry.
Read more from the original source:
Hiltzik: The battle against unlicensed stem cell clinics - Los Angeles Times